Posted: February 27th, 2023

research

Review Article
Hydration Strategies for Preventing Contrast-Induced Acute
Kidney Injury: A Systematic Review and Bayesia

Network Meta-Analysi

Qiuping Cai, Ran Jing, Wanfen Zhang, Yushang Tang, Xiaoping Li, and Tongqiang Liu

Division of Nephrology, �e Affiliated Changzhou NO.2 People’s Hospital of Nanjing Medical University, Changzhou 213003,
Jiangsu, China

Correspondence should be addressed to Tongqiang Liu; liuyf1106@126.com

Received 25 May 2019; Accepted 31 December 2019; Published 11 February 202

Academic Editor: Paul M. Grossman

Copyright © 2020 Qiuping Cai et al. -is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.

Aims. Many previous studies have examined the effect of different hydration strategies on prevention of contrast-induced acute
kidney injury (CI-AKI), but the optimal strategy is unknown. We performed a network meta-analysis (NWM) of these previous
studies to identify the optimal strategy. Methods and Results. Web of Science, PubMed, OVID Medline, and Cochrane Librar

were searched from their inception dates to September 30, 2018. Randomized controlled trials (RCTs) were selected based on strict
inclusion criteria, and a Bayesian NWM was performed using WinBUGS V.1.4.3. We finally analyzed 60 eligible RCTs, which
examined 21,293 patients and 2232 CI-AKI events. Compared to intravenous 0.9% sodium chloride (reference), intravenous
sodium bicarbonate (OR [95% CI]: 0.74 [0.57, 0.93]), hemodynamic guided hydration (0.41 [0.18, 0.93]), and RenalGuard guided
hydration (0.32 [0.14, 0.70]) significantly reduced the occurrence of CI-AKI. Oral hydration and intravenous 0.9% sodium
chloride were each noninferior to no hydration in preventing CI-AKI. Intravenous 0.9% sodium chloride, sodium bicarbonate,
and hemodynamic guided hydration were each noninferior to oral hydration in preventing CI-AKI. Based on surface under the
cumulative ranking curve values, the RenalGuard system was best (0.974) and hemodynamic guided hydration was second best
(0.849). Conclusion. -ere was substantial evidence to support the use of RenalGuard or hemodynamic guided hydration for
preventing CI-AKI in high-risk patients, especially those with chronic kidney disease or cardiac dysfunction.

1. Introduction

Contrast-induced acute kidney injury (CI-AKI), also re-
ferred to as contrast-induced nephropathy (CIN), is an
iatrogenic complication that can occur following intravas-
cular administration of iodinated contrast medium (CM

)

prior to radiography. CI-AKI is the third leading cause of
hospital-acquired acute renal injury (AKI) [1]. CI-AKI has a
low incidence in the general population, but it has a sig-
nificant incidence in patients with certain risk factors.
Moreover, the occurrence of CI-AKI following cardiac
catheterization procedures is associated with an in-hospital
mortality of 20%, a 1-year mortality of up to 66%, and an
even higher mortality in patients who require dialysis [2, 3].
However, even if patients with high risk of CI-AKI can be

identified a priori, no known pharmaceutical treatment can
effectively prevent or treat CI-AKI.

Guidelines recommend intravascular hydration to pre-
vent CI-AKI [4, 5], and there are several specific hydration
strategies, but researchers have not yet established an op-
timal strategy [6–9]. Notably, recent randomized controlled
trials (RCTs) have led to doubts about the effectiveness of
various hydration strategies in prevention of CI-AKI. For
example, Nijssen et al. [10] conducted an RCTwith 660 high-
risk patients and found that no prophylaxis was noninferior
or cost-saving relative to intravenous hydration. Weisbord
et al. [11] enrolled 5177 high-risk patients and reported no
benefit of intravenous sodium bicarbonate relative to normal
saline. Another RCT [12] concluded that the benefit of
sodium bicarbonate was marginal relative to isotonic

Hindawi
Journal of Interventional Cardiology
Volume 2020, Article ID 7292675, 16 pages
https://doi.org/10.1155/2020/7292675

mailto:liuyf1106@126.com

https://orcid.org/0000-0002-5990-725

https://creativecommons.org/licenses/by/4.0/

https://doi.org/10.1155/2020/729267

sodium chloride for preventing CI-AKI among critically ill
patients. However, other studies indicated that the Renal-
Guard System [13–16] and hemodynamic guided hydration
[17–19] were safe and effective in preventing CI-AKI. Be-
cause of these apparently discrepant results, we conducted a
network meta-analysis (NMA) to assess the effects of various
hydration strategies on the occurrence of CI-AKI in an effort
to identify the optimal strategy for prevention of CI-AKI.

2. Methods

2.1. Data Search. -is systematic review and meta-analysis
were performed according to Cochrane Handbook guide-
lines [20].-eWeb of Science, PubMed, OVIDMedline, and
Cochrane Library databases were searched using medical
subject headings or keywords. Relevant published original
studies that were published up to September 30, 2018, were
examined. -e search syntax was as follows: “contrast-in-
duced acute kidney injury OR contrast-induced nephrop-
athy OR CIN OR CI-AKI OR contrast acute renal failure OR
contrast nephropathy” AND “hydration OR fluid admin-
istration OR volume expansion OR intravenous sodium
bicarbonate OR saline infusion.”

2.2. Study Selection. An initial eligibility screen of all cita-
tions was conducted, and only studies that examined CI-AKI
and hydration were selected for further full-text review. All
included studies were RCTs; experimental studies were
excluded. In addition, all included studies reported the
prevention of CI-AKI after intravascular administration of
CM; used clinical protocols that were hydration strategies,
not pharmaceutical prevention strategies; had clear defini-
tions of CI-AKI; and provided data on the outcome of in-
terest (occurrence of CI-AKI within 2 days to 1 week after
procedures).

2.3. Data Extraction and Quality Assessment. Two authors
(C. Q. P. and J. R.) independently reviewed each article for
eligibility. Any disagreement was resolved by discussion
among the authors or involvement of a third author. Data
extraction included the year of publication, sample size, pa-
tient characteristics, risk factors associated with CI-AKI (old
age, diabetes mellitus, renal impairment, heart failure), and
type and dosage of contrast medium. -e primary endpoint
was the occurrence of CI-AKI within 2 days to 1 week after
intravascular administration of CM. Two investigators inde-
pendently evaluated the quality of each study using the Jadad
scale, which ranges from 0 (worst) to 5 (best) [21].

2.4. Statistical Analyses. -e advantages of Bayesian NM

over traditional meta-analysis are its greater flexibility, its
provision of more naturally interpretable results, and its
ability to rank treatments by comparative effectiveness [22].
-e occurrence of CI-AKI as a dichotomous outcome
variable was expressed as an odds ratio (OR) and 95%
confidence interval (CI). All P values were 2-sided, and a P

value below 0.05 was considered significant. All analyses

were conducted using the Bayesian Markov chain Monte
Carlo method inWinBUGS V.1.4.3 (MRC Biostatistics Unit,
Cambridge, United Kingdom) using the Microsoft Excel-
based macro NetMetaXL V.1.6.1 (Canadian Agency for
Drugs and Technologies in Health, Ottawa, Canada) [23]. A
convergence test for each analysis was conducted by
checking whether the Monte Carlo error was less than 5% of
the SD of the effect estimates or the variance between the
studies. Convergence was achieved for all analyses using
1000 “burn in” runs and 1000 model runs. NetMetaXL was
also used to generate a forest plot, league table, and “ran-
kogram” with surface under the cumulative ranking curve
(SUCRA), which ranges from 0 (worst) to 100% (best).
Inconsistency was assessed by comparing the residual de-
viance and deviance information criterion statistics in fitted
consistency and inconsistency models.

3. Results

3.1. Literature Search. We initially identified 3620 publica-
tions, assessed 703 RCTs for eligibility by review of the full
texts, and ultimately included 60 RCTs which met the eli-
gibility criteria (Figure 1). -ese studies examined 21,29

patients (median: 222, interquartile range [IQR]: 120, 350)
and 2232 CI-AKI events. All included RCTs were full-length
journal articles. Agreement between the two reviewers at the
full-text review stage was excellent (Cohen’s κ� 0.85).

3.2.Characteristics of Studies andParticipants. Table 1 shows
the characteristics of the included studies. -e publication
date ranged from 2002 to 2018, and about 50% of the studies
were published after 2013. -e proportion of male patients
ranged from 25.0% to 98.1% (median [IQR]: 65.7 [56.9,
74.8]), and the mean age ranged from 56.2 to 82.9 years (67.8
[63.1, 72.5]).-irty-one studies enrolled 12,519 patients who
had high risk of CI-AKI.-e baseline serum creatinine (SCr)
level ranged from 61.4 to 236.4 μmol/L (117.1 [89.5, 136.9]),
and the baseline estimated glomerular filtration rate (eGFR)
ranged from 32 to 93.1mL/min/1.73m2 (49.2 [44.1, 74.2]).
Twenty-three studies provided the values of left ventricular
ejection fraction (LVEF); the mean LVEF ranged from 25%
to 57.8% (49.0 [42.8, 54.5]). -e percentage of diabetes
mellitus (DM) patients ranged from 8% to 100%, and the
percentage with heart failure (HF) ranged from 0.6% to
45.8%. A total of 8176 patients from 32 studies received
intravenous low-osmolar nonionic CM, 9993 patients from
17 studies received iso-osmolar nonionic CM, and 317
patients from 2 studies received low-osmolar ionic CM. -e
mean Jadad score of the 60 RCTs was 3.2 (3 [2, 4]), indicating
the overall study quality was good.

3.3. Network Meta-Analysis. Figure 2 shows all the com-
parisons in the NMA. -irty-seven studies (13,365 partici-
pants) compared the efficacy of intravenous sodium
bicarbonate and 0.9% sodium chloride. -e other hydration
strategies were nonhydration (8 studies, 1396 patients), oral
hydration (6 studies, 355 patients), intravenous half iso-
osmolar saline (3 studies, 968 patients), intravenous

2 Journal of Interventional Cardiology

hydration, mainly normal saline + diuresis (

2 studies

[26, 31], 501 patients), hemodynamic guided hydration (3
studies, 458 patients), and RenalGuard system guided hy-
dration (4 studies, 348 patients).

We compared the ORs of the different hydration
strategies using a forest plot (Figure 3) and analyzed the
results of the random effects consistency NMA using a
league table, which shows all pairwise comparisons (Figure 4).
Taken together, these results indicate that, relative to typical
intravenous 0.9% sodium chloride hydration (reference), the
occurrence of CI-AKI was significantly reduced by intra-
venous sodium bicarbonate (OR [95% CI]: 0.74 [0.57, 0.93]),
hemodynamic guided hydration (0.41 [0.18, 0.93]), and
RenalGuard system guided hydration (0.32 [0.14, 0.70]).
Oral hydration (0.72 [0.28, 1.82]) and intravenous 0.9%
sodium chloride (0.64 [0.39, 1.08]) were each noninferior to
no hydration for prevention of CI-AKI. Relative to oral
hydration (reference), intravenous 0.9% sodium chloride or
sodium bicarbonate and hemodynamic guided hydration
were each noninferior in prevention of CI-AKI, but
RenalGuard guided hydration was superior (0.21 [0.07,
0.63]). Intravenous hydration plus diuresis also did not
decrease the risk of CI-AKI relative to oral hydration and no
hydration.

A rankogram and SUCRA values indicated the Renal-
Guard system was best (SUCRA� 0.974) followed by he-
modynamic guided hydration (SUCRAs� 0.849; Figure 5).
Intravenous sodium bicarbonate had a SUCRA of 0.667.-e
SUCRAs for intravenous 0.9% sodium chloride, intravenous
hydration plus diuresis, oral and no hydration, and the other

treatments ranged from 0.197 to 0.441, and their rankings
were similar. Hydration using half iso-osmolar saline alone
was the least effective treatment.

3.4. Inconsistency Analysis. We performed network incon-
sistency assessment for the fixed effect model for the 60
studies (Figure 6). -e resulting plot demonstrated that
nearly all the studies were near the line of equality and that
the results were therefore consistent. However, there was
some evidence of inconsistency in 3 noninferiority studies
[10, 31]. In particular, Martin-Moreno et al. [31] and Nijssen
et al. [10] found that intravenous sodium bicarbonate and
0.9% sodium chloride were noninferior to oral hydration.

4. Discussion

To our knowledge, this is the first NMA to compare different
hydration strategies for prevention of CI-AKI. We included
60 RCTs which examined 21,293 participants and 2232 CI-
AKI events. Our comparison of 8 hydration strategies for
preventing CI-AKI confirmed that, relative to intravenous
0.9% sodium chloride hydration, three treatments during
CM administration significantly reduced the risk for CI-
AKI: the RenalGuard system, hemodynamic guided hy-
dration, and intravenous sodium bicarbonate. Relative to no
hydration, oral hydration and intravenous 0.9% sodium
chloride were each noninferior in prevention of CI-AKI.
Relative to oral hydration, intravenous 0.9% sodium chlo-
ride and sodium bicarbonate were each noninferior

prevention of CI-AKI. -us, we ranked the

RenalGuard

system as the best strategy and hemodynamic guided hy-
dration as the second best.

Guidelines for the prevention of CI-AKI in high-risk
patients routinely recommend hydration protocols before
contrast exposure as an established preventive measure
[77, 78]. A recent large RCT [10] led us to reanalyze the
efficacy of hydration for prevention of CI-AKI. In particular,
the AMAstricht Contrast-Induced Nephropathy Guideline
(AMACING) study [10] enrolled 660 patients with high risk
of CI-AKI and concluded that, relative to intravenous hy-
dration, no prophylaxis was less expensive and noninferior
in prevention of CI-AKI. In our meta-analysis, five studies
compared the effectiveness of intravenous 0.9% sodium
chloride and three studies compared bicarbonate with
nonhydration, leading to our conclusion that, relative to no
hydration (reference), oral hydration or hydration with
intravenous 0.9% sodium chloride was noninferior in pre-
vention of CI-AKI. -ese results were unsurprising, because
simple oral or intravenous hydration can lead to compli-
cations, such as heart failure, pulmonary edema, and elec-
trolyte disorders. -us, the safety window of hydration is
relatively narrow for patients undergoing percutaneous
coronary intervention (PCI), and other more effective or
precise hydration strategies may be needed to decrease the
incidence of CI-AKI.

Most meta-analyses before 2016 [79–83] confirmed that
intravenous sodium bicarbonate was more effective than
sodium chloride in preventing CI-AKI. However, two recent

3620 citations identified
2348 identified through Web of Science search
411 identified through PubMed search
431 identified through Cochrane Library search
430 identified through OVID search

847 excluded
748 were not RCTs
99 were reviews or comments

643 excluded
339 were not about hydration
220 had no outcomes of interest
84 were protocols

2070 excluded during initial screen for not
meeting inclusion criteria
1534 were duplicates
536 had unrelated population or outcome

1550 studies screened in full-text review

703 RCTs assessed for eligibility

60 RCTs included in final analysis

Figure 1: Identification and selection of studies for Bayesian
network meta-analysis.

Journal of Interventional Cardiology 3

Ta
bl

e
1:

ha
ra
ct
er
i

st
ic

s
of

th
e

in
cl
ud

ed
st
ud

ie
s.

St
ud

ie
s

Pa
tie
nt
s

(n
)

In
cl
us
io
n

cr
ite
ri
a/

ri
sk

C
I-

A
K
I

M
ea
n

ag
e

(y
ea
rs
)

M
al
es

(%
)

se
lin

e
SC

r
(m

g/
d

)

Ba
se
lin

e
e

FR
(m

L/
m

in
/

1.
73

2 )

M
ea
n

V
E

(%
)

Tr
ea
tm

en
t

gr
ou

s
Ty

pe
s
of

C
M

do
sa
ge

(m
L)

Ja
da
d

sc
or
e

N
o.

pa
tie
nt
s

In
cl
us
io
n

cr
ite
ri
a/
ri
sk

of
C
I-
A
K
I

M
ea
n

ag
e

M
al
e

(%
)

Ba
se
lin

e
SC

r
Ba

se
lin

e
eG

FR
M
ea
n

LV
EF

D
M

(%
)

H
F

(%
)

ro
up

s
Ty

pe
s
of

C
M

D
os
ag
e

of
C
M

Ja
da
d

sc
or
e

W
ei
sb
or
d

et
al
.[
11
]

H
ig
h
ri
sk

fo
r

na
l

co
m
pl
ic
at
io
ns

an
d

sc
he
du

le
d

fo
ra

ng
io
gr
ap
hy

69
.8

93
.6

13
2.
6

50
.

SC
vs

Io
di
xa
no

lo
r
lo
w
–

os
m

ol
ar

85
5

49
93

H
ig
h
ri
sk

fo
r

re
na
l

co
m
pl
ic
at
io
ns

an
d
sc
he
du

le
d

fo
r

an
gi
og
ra
ph

69
.8

93
.6

13
2.
6

50
.2

80
.9

7.
4

vs
.S

B
Io
di
xa
no

lo
rl
ow

–

os
m
ol
ar

85
5

va
n
M
ou

ri
k

et
al
.[
24
]

Sy
m
pt
om

at
ic

ao
rt
ic

va
lv
e

st
en
os
is
an
d

im
pa
ir
ed

re
na
l

fu
nc
tio

w
ho

un
de
rw

en
tp

re
–

TA
V
I
C
TA

82
.9

44
.6

10
4.
3

47
.4

31
.1

SC
vs
.S

Io
pr
om

id
e

90
3

Sy
m
pt
om

at
ic

ao
rt
ic

va
lv
e

st
en
os
is
an
d

im
pa
ir
ed

re
na
l

fu
nc
tio

n
w
ho

un
de
rw

en
tp

re
–

TA
V
I
C
TA

82
.9

44
.6

10
4.
3

47
.4

31
.1

SC
vs

B
Io
pr
om

id
e

90
3

Sa
ra
tz
is
et

al
.

[2
5]

El
ec
tiv

e
EV

A
R

fo
r
in
fr
ar
en
al

A
A
A

75
89

65
.5

13
.8

SC
vs
.S

Io
m
ep
ro
l

12
6

3
58

El
ec
tiv

e
EV

A
R

fo
r
in
fr
ar
en
al

A
A
A

75
89
.7

65
.5

13
.8

SC
vs

SB
Io
m
ep
ro
l

12
6

M
ai
ol
ie

ta
l.

[1
8]

29
6

El
ec
tiv

co
ro
na
ry

an
gi
og
ra
ph

pr
oc
ed
ur
es

71
68
.2

89
.3

48
24
.7

SC
vs
.H

D
y

Io
di
xa
no

l
13
1

3
29
6

El
ec
tiv

e
co
ro
na
ry

an
gi
og
ra
ph

ic
pr
oc
ed
ur
es

71
68
.2

89
.3

48
24
.7

SC
vs

H
D
y

Io
di
xa
no

l
13
1

K
oo

im
an

t
al
.

[2
6]

33
3

C
K
D

pa
tie
nt
s

de
rg
oi
ng

ec
tiv

e
ca
rd
io

va
sc
ul
ar

di
ag
no

st
ic

in
te
rv
en
tio

na
l

co
nt
ra
st

pr
oc
ed
ur
es

64
.6

50
.5

38
.7

16
.5

SC
vs
.S

N
ot

m
en
tio

ne
d

11
3

3
33
3

C
K
D

pa
tie
nt
s

un
de
rg
oi
ng

el
ec
tiv

e
ca
rd
io
va
sc
ul
ar

di
ag
no

st
ic

or
in
te
rv
en
tio

na
l

co
nt
ra
st

pr
oc
ed
ur
es

73
64
.6

50
.5

38
.7

16
.5

SC
vs

B
N
ot

m
en
tio

ne
d

11
3

V
al
et
te

et
al
.

[1
2]

30
7

C
ri
tic
al
ly

ill

pa
tie
nt
s

w
ith

st
ab
le

re
na
l

fu
nc
tio

n
w
ho

re
ce
iv
ed

in
tr
av
as
cu
la
r

C
M

56
.2

67
.8

61
.4

13
.4

6.
5

SC
vs
.S

B
Lo

w
-o
sm

ol
ar

90
4

30
7

C
ri
tic
al
ly

ill

pa
tie
nt
s
w
ith

st
ab
le

re
na
l

fu
nc
tio

n
w
ho

re
ce
iv
ed

in
tr
av
as
cu
la
r

C
M

56
.2

67
.8

61
.4

13
.4

6.
5

SC
vs

SB
Lo

w
-o
sm

ol
ar

90
4

N
ijs
se
n
et

al
.

[1
0]

66
0

H
ig
h-
ri
sk

pa
tie
nt
s
w
ith

eG
FR

of
30
–5
9
m
l/m

in
/

1.
73

m
2 ,

un
de
rg
oi
ng

an
el
ec
tiv

e
pr
oc
ed
ur
e

re
qu

ir
in
g

C
M

ad
m
in
ist
ra
tio

61
.7

11
8

47
.4

32
.6

N
on

vs
.S

C
Io
pr
om

id
e

90
.5

3
66
0

H
ig
h-
ri
sk

pa
tie
nt
s
w
ith

eG
FR

of
30
–5
9
m
l/m

in
/

1.
73

m
2 ,

un
de
rg
oi
ng

an
el
ec
tiv

e
pr
oc
ed
ur
e

re
qu

ir
in
g
C
M

ad
m
in
ist
ra
tio

72
61
.7

11
8

47
.4

32
.6

N
on

s
SC

Io
pr
om

id
e

90
.5

A
lo
ns
o
et

al
.

[2
7]

Pa
tie
nt
s

re
ce
iv
in
g

C
M

du
ri
ng

C
RT

de
vi
ce
s

pl
an
ta
tio

66
.5

65
.3

11
0.
5

28
.5

37
SC

vs
.S

B
Io
di
xa
no

10
2

2
93

Pa
tie
nt
s

re
ce
iv
in
g
C
M

du
ri
ng

C
RT

de
vi
ce
s

im
pl
an
ta
tio

66
.5

65
.3

11
0.
5

28
.5

37
SC

vs
SB

Io
di
xa
no

l
10
2

U
sm

ia
ni

et
al
.

[2
8]

12
4

C
or
on

ar
y

an
gi
og
ra
ph

y/
PC

I
w
ith

eG
FR

of
le
ss

th
an

0
m
l/m

in
/

1.
73

m
2

75
74

13
0.
8

44
25

84
SC

vs
.

na
lG
ua
rd

Io
di
xa
no

15
6

3
12
4

C
or
on

ar
y

an
gi
og
ra
ph

y/
PC

I
w
ith

eG
FR

of
le
ss

th
an

60
m
l/m

in
/

1.
73

m
2

75
74

13
0.
8

44
25

84
SC

vs
Re

na
lG
ua
rd

Io
di
xa
no

l
15
6

Tu
re
di

et
al
.

[2
9]

17
2

C
on

tr
as
t-

en
ha
nc
ed

C
TP

A
on

su
sp
ic
io
n
of

w
ith

le
as
to

ne
ri
sk

fa
ct
or

fo
r

C
IN

75
.5

51
.7

85
.4

SC
vs
.S

B
W
at
er
-s
ol
ub

le
,

no
ni
on

ic
,l
ow

–
os
m
ol
ar

<1
00

3
17
2

C
on

tr
as
t-

en
ha
nc
ed

C
TP

A
on

su
sp
ic
io
n
of

PE
w
ith

at
le
as
t

on
e
ri
sk

fa
ct
or

fo
r
C
IN

75
.5

51
.7

85
.4

SC
vs

SB
W
at
er
-s
ol
ub

le
,

no
ni
on

ic
,l
ow

–
os
m
ol
ar

<1
00

4 Journal of Interventional Cardiology

Ta
bl

e
1:

C
on

tin
ue
d.

St
ud

ie
s

Pa
tie
nt
s

(n
)

In
cl
us
io
n

cr
ite
ri
a/
ri
sk

of
C
I-
A
K
I

M
ea
n

ag
e

(y
ea
rs
)

M
al
es

(%
)

Ba
se
lin

e
SC

r
(m

g/
dL

)

Ba
se
lin

e
eG

FR
(m

L/
m
in
/

1.
73

m
2 )

M
ea
n

LV
EF

(%
)

D
M

(%
)

H
F

(%
)

Tr
ea
tm

en
t

gr
ou

ps
Ty

pe
s
of

C
M

do
sa
ge

(m
L)

Ja
da
d

sc
or
e

N
o.

of
pa
tie
nt
s

In
cl
us
io
n

cr
ite
ri
a/
ri
sk

of
C
I-
A
K
I

M
ea
n

ag
e

M
al
e

(%
)

Ba
se
lin

e
SC

r
Ba

se
lin

e
eG

FR
M
ea
n

LV
EF

D
M

(%
)

H
F

(%
)

G
ro
up

s
Ty

pe
s
of

C
M

D
os
ag
e

of
C
M

Ja
da
d

sc
or
e

Q
ia
n
et
al
.[
19
]

26
4

C
K
D

an
d
C
H
F

un
de
rg
oi
ng

co
ro
na
ry

pr
oc
ed
ur
es

63
.5

74
.6

15
1

37
.5

39
.5

47
.3

SC
vs
.H

D
y

Io
di
xa
no

l
16
6

5
26
4

C
K
D

an
d
C
H
F

un
de
rg
oi
ng

co
ro
na
ry

pr
oc
ed
ur
es

63
.5

74
.6

15
1

37
.5

39
.5

47
.3

SC
vs

H
D
y

Io
di
xa
no

l
16
6

So
lo
m
on

et
al
.

[3
0]

39
1

El
ec
tiv

e
co
ro
na
ry

or
pe
ri
ph

er
al

an
gi
og
ra
ph

y
w
ith

eG
FR

<4
5
m
l/m

in
/

1.
73

m
2

57
.5

16
9.
3

32
.8

35
.5

SC
vs
.S

B
N
ot

m
en
tio

ne
d

10
7

4
39
1

El
ec
tiv

e
co
ro
na
ry

or
pe
ri
ph

er
al

an
gi
og
ra
ph

y
w
ith

eG
FR

<4
5
m
l/m

in
/

1.
73

m
2

72
57
.5

16
9.
3

32
.8

59
.1

35
.5

SC
vs

SB
N
ot

m
en
tio

ne
d

10
7

M
ar
tin

–
M
or
en
o
et

al
.

[3
1]

13
0

Re
ce
iv
in
g
C
M

fo
r

C
T

sc
an

57
.5

64
.3

79
.6

N
on

vs
SB

N
ot

m
en
tio

ne
d

12
0

3
13
0

Re
ce
iv
in
g
C
M

fo
r
C
T
sc
an

57
.5

64
.3

79
.6

N
on

vs
SB

N
ot

m
en
tio

ne
d

12
0

Ju
ra
do

–
Ro

m
án

et
al
.

[3
2]

40
8

ST
EM

I
un

de
rg
oi
ng

r
im

ar
y
PC

I
63
.1

73
.4

89
22
.5

14
.7

N
on

vs
.S

Is
o-
os
m
ol
ar

no
ni
on

ic
17
4

2
40
8

ST
EM

I
un

de
rg
oi
ng

pr
im

ar
y
PC

I
63
.1

73
.4

89
22
.5

14
.7

N
on

vs
SC

Is
o-
os
m
ol
ar

no
ni
on

ic
17
4

Ba
rb
an
ti
et

al
.

[1
3]

11
2

TA
V
R

81
40
.2

87
.1

51
.5

54
.6

25
SC

vs
.

Re
na
lG
ua
rd

Bu
ck
in
gh

am
sh
ir
e

17
5

3
11
2

TA
V
R

81
40
.2

87
.1

51
.5

54
.6

25
SC

vs
Re

na
lG
ua
rd

Bu
ck
in
gh

am
sh
ir
e

17
5

Ye
ga
ne
hk

ha
h

et
al
.[
33
]

10
0

C
A
G

59
.7

99
.5

43
.8

39
SC

vs
.S

Io
he
xo
l

45
.4

3
10
0

C
A
G

59
.7

53
99
.5

43
.8

39
SC

vs
SB

Io
he
xo
l

45
.4

Ya
ng

et
al
.

[3
4]

32
0

El
ec
tiv

e
ca
rd
io
va
sc
ul
ar

pr
oc
ed
ur
es

in
cl
ud

in
g
C
A
G

or
in
te
rv
en
tio

na
l

tr
ea
tm

en
t

59
.2

53
.1

70
.2

93
.1

55
.1

20
SC

+
N
A
C

vs
.

SB
+
N
A
C

Io
pr
om

id
e

12
5

3
32
0

El
ec
tiv

e
ca
rd
io
va
sc
ul
ar

pr
oc
ed
ur
es

in
cl
ud

in
g
C
A
G

or
in
te
rv
en
tio

na
l

tr
ea
tm

en
t

59
.2

53
.1

70
.2

93
.1

55
.1

20
SC

+
N
A
C
vs

SB
+
N
A
C

Io
pr
om

id
e

12
5

Ya
ng

et
al
.

[3
4]

32
0

El
ec
tiv

e
ca
rd
io
va
sc
ul
ar

pr
oc
ed
ur
es

in
cl
ud

in
g
C
A
G

or
in
te
rv
en
tio

na
l

tr
ea
tm

en
t

59
.2

53
.1

70
.2

93
.1

55
.1

20
SC

vs
.S

B
Io
pr
om

id
e

12
5

3
32
0

El
ec
tiv

e
ca
rd
io
va
sc
ul
ar

pr
oc
ed
ur
es

in
cl
ud

in
g
C
A
G

or
in
te
rv
en
tio

na
l

tr
ea
tm

en
t

59
.2

53
.1

70
.2

93
.1

55
.1

20
SC

vs
SB

Io
pr
om

id
e

12
5

–
ay
ss
en

et
al
.

[3
5]

36
2

ST
EM

I
un

de
rg
oi
ng

pr
im

ar
y
PC

I
w
ith

in
12

ho
ur
s

fr
om

th
e
on

se
t

of
ch
es
tp

ai
n

62
.5

78
.5

77
90
.5

50
9.
7

SC
vs
.S

B
Io
di
xa
no

l
14
0

5
36
2

ST
EM

I
un

de
rg
oi
ng

pr
im

ar
y
PC

I
w
ith

in
12

ho
ur
s

fr
om

th
e
on

se
t

of
ch
es
tp

ai
n

62
.5

78
.5

77
90
.5

50
9.
7

SC
vs

SB
Io
di
xa
no

l
14
0

N
ie
to
-R
io
s

et
al
.[
36
]

22
0

To
m
og
ra
ph

y
sc
an

us
in
g
C
M

or
an
gi
og
ra
ph

y
60

57
.7

11
5.
8

37
.3

SC
vs
.S

B
Io
he
xo
l

10
0

3
22
0

To
m
og
ra
ph

y
sc
an

us
in
g
C
M

or
an
gi
og
ra
ph

y
60

57
.7

11
5.
8

37
.3

SC
vs

SB
Io
he
xo
l

10
0

M
an
ar
ie

ta
l.

[3
7]

59
2

ST
EM

I
w
ith

in
12

h
fr
om

sy
m
pt
om

on
se
t

re
fe
rr
ed

fo
r

pr
im

ar
y

an
gi
op

la
st
y

65
74
.8

88
.5

81
48

16
.6

11
.8

SC
vs
.S

B
Io
di
xa
no

l
19
8

3
59

ST
EM

I
w
ith

in
12

h
fr
om

sy
m
pt
om

on
se
t

re
fe
rr
ed

fo
r

pr
im

ar
y

an
gi
op

la
st
y

65
74
.8

88
.5

81
48

16
.6

11
.8

SC
vs

SB
Io
di
xa
no

l
19
8

M
ah
m
oo

di
et

al
.[
38
]

35
0

C
or
on

ar
y

in
te
rv
en
tio

ns
64
.4
8

51
.4

10
3

64
.8

SC
vs
.S

B
Io
he
xo
l

2
35
0

C
or
on

ar
y

in
te
rv
en
tio

ns
64
.4
8

51
.4

10
3

64
.8

SC
vs

SB
Io
he
xo
l

Lu
o
et

al
.[
39
]

21
6

ST
EM

I
67

65
.7

77
77
.6

25
N
on

vs
.S

Io
pa
m
ir
on

23
4.
9

3
21
6

ST
EM

I
67

65
.7

77
77
.6

25
N
on

vs
SC

Io
pa
m
ir
on

23
4.
9

K
oo

im
an

et
al
.

[4
0]

54
8

C
K
D

pa
tie
nt
s

re
ce
iv
in
g
C
E-

C
T

72
.1

60
.4

50
.4

26
.8

16
.4

SC
vs
.S

B
Io
m
ep
ro
l

10
5

5
54
8

C
K
D

pa
tie
nt
s

re
ce
iv
in
g
C
E-

C
T

72
.1

60
.4

50
.4

26
.8

16
.4

SC
vs

SB
Io
m
ep
ro
l

10
5

K
oo

im
an

et
al
.

[4
1]

13
8

C
K
D

pa
tie
nt
s

re
ce
iv
in
g
C
TP

A
70
.5

50
49
.2

16
.7

8
N
on

vs
.S

B
Io
pr
om

e
or

io
bi
tr
id
ol

r
io
di
xa
no

l
74

5
13
8

C
K
D

pa
tie
nt
s

re
ce
iv
in
g

C
TP

A
70
.5

50
49
.2

16
.7

8
N
on

vs
SB

Io
pr
om

id
e,
or

io
bi
tr
id
ol
,o

r
io
di
xa
no

l
74

Journal of Interventional Cardiology 5

Ta
bl

e
1:

C
on

tin
ue
d.

St
ud

ie
s

Pa
tie
nt
s

(n
)

In
cl
us
io
n

cr
ite
ri
a/
ri
sk

of
C
I-
A
K
I

M
ea
n

ag
e

(y
ea
rs
)

M
al
es

(%
)

Ba
se
lin

e
SC

r
(m

g/
dL

)

Ba
se
lin

e
eG

FR
(m

L/
m
in
/

1.
73

m
2 )

M
ea
n

LV
EF

(%
)

D
M

(%
)

H
F

(%
)

Tr
ea
tm

en
t

gr
ou

ps
Ty

pe
s
of

C
M

do
sa
ge

(m
L)

Ja
da
d

sc
or
e

N
o.

of
pa
tie
nt
s

In
cl
us
io
n

cr
ite
ri
a/
ri
sk

of
C
I-
A
K
I

M
ea
n

ag
e

M
al
e

(%
)

Ba
se
lin

e
SC

r
Ba

se
lin

e
eG

FR
M
ea
n

LV
EF

D
M

(%
)

H
F

(%
)

G
ro
up

s
Ty

pe
s
of

C
M

D
os
ag
e

of
C
M

Ja
da
d

sc
or
e

Br
ar

et
al
.[
17
]

39
6

Re
fe
rr
ed

to
th
e

ca
rd
ia
c

ca
th
et
er
iz
at
io
n

la
bo

ra
to
ry

w
ith

eG
FR
≤
60

m
L/

m
in
/1
.7
3
m

2 ,
an
d
at

le
as
to

ne
of

th
ef
ol
lo

w
in
g:

D
M
,C

H
F,

hy
pe
rt
en
sio

n,
or

ag
e
ol
de
r

th
an

75
ye
ar
s

72
61
.9

12
3.
8

48
51
.3

20
.5

SC
vs
.H

D
y

Io
xi
la
n

10
8

3
39
6

Re
fe
rr
ed

to
th
e

ca
rd
ia
c

ca
th
et
er
iz
at
io
n

la
bo

ra
to
ry

w
ith

eG
FR
≤
60

m
L/

m
in
/1
.7
3
m

2 ,
an
d
at

le
as
to

ne
of

th
e

fo
llo

w
in
g:

D
M
,

C
H
F,

hy
pe
rt
en
sio

n,
or

ag
e
ol
de
r

th
an

75
ye
ar
s

72
61
.9

12
3.
8

48
51
.3

20
.5

SC
vs

H
D
y

Io
xi
la
n

10
8

A
ky
uz

et
al
.

[4
2]

22
5

A
tl
ea
st

on
e
of

th
e

hi
gh

-r
isk

fa
ct
or
s

fo
r

de
ve
lo
pi
ng

C
I-

A
K
I
an
d

un
de
rg
oi
ng

C
A
G

an
d/
or

PC
I

63
.4

68
.9

79
.6

84
.5

47
.5

60
.9

7.
6

O
ra
lv

s.
SC

N
ot

m
en
tio

ne
d

10
8

2
22
5

A
tl
ea
st

on
e
of

th
e
hi
gh

-r
isk

fa
ct
or
s
fo
r

de
ve
lo
pi
ng

C
I-

A
K
I
an
d

un
de
rg
oi
ng

C
A
G

an
d/
or

PC
I

63
.4

68
.9

79
.6

84
.5

47
.5

60
.9

7.
6

O
ra
lv

s
SC

N
ot

m
en
tio

ne
d

10
8

K
ri
st
el
le
re

ta
l.

[4
3]

St
ag
e
3
or

hi
gh

er
C
K
D

w
ho

un
de
rw

en
t

ca
rd
ia
c

su
rg
er
y

us
in
g

C
PB

72
.5

57
.6

11
9.
1

44
.6

34
.8

SC
vs

SB
N
ot

m
en
tio

ne
d

79
5

St
ag
e
3
or

hi
gh

er
C
K
D

w
ho

un
de
rw

en
t

ca
rd
ia
c
su
rg
er
y

us
in
g
C
PB

72
.5

57
.6

11
9.
1

44
.6

34
.8

SC
vs

SB
N
ot

m
en
tio

ne
d

79
5

K
oc

et
al
.[
44
]

19
5

D
M

pa
tie
nt
s

62
52
.3

88
.4

10
0

SC
vs
.S

B
N
ot

m
en
tio

ne
d

90
4

19
5

D
M

pa
tie
nt
s

62
52
.3

88
.4

10
0

SC
vs

SB
N
ot

m
en
tio

ne
d

90
4

G
u
et

al
.[
45
]

85
9

C
or
on

ar
y

an
gi
og
ra
ph

y
or

an
gi
op

la
st
y

72
.2

90
.1

74
.2

20
.6

0.
6

SC
vs
.

+
di
ur
es
is

N
ot

m
en
tio

ne
d

10
0

2
85
9

C
or
on

ar
y

an
gi
og
ra
ph

y
or

an
gi
op

la
st
y

59
72
.2

90
.1

74
.2

20
.6

0.
6

SC
vs

SC
+
di
ur
es
is

N
ot

m
en
tio

ne
d

10
0

Bo
uc
ek

et
al
.

[4
6]

12
0

D
ia
be
tic

pa
tie
nt
s
w
ith

im
pa
ir
ed

re
na
l

fu
nc
tio

n,
un

de
rg
oi
ng

in
tr
a-
ar
te
ri
al

in
tr
av
en
ou

s
us
e

of
C
M

65
75

16
5

44
.1

10
0

SC
vs
.S

B
Lo

w
-o
sm

ol
ar

no
ni
on

ic
io
di
na

te
d

11
0

5
12
0

D
ia
be
tic

pa
tie
nt
s
w
ith

im
pa
ir
ed

re
na
l

fu
nc
tio

n,
un

de
rg
oi
ng

in
tr
a-
ar
te
ri
al
or

in
tr
av
en
ou

su
se

of
C
M

65
75

16
5

44
.1

10
0

SC
vs

SB
Lo

w
-o
sm

ol
ar

no
ni
on

ic
io
di
na
te
d

11
0

M
ar
en
zi

et
al
.

[4
7]

17
0

C
K
D

un
de
rg
oi
ng

co
ro
na
ry

pr
oc
ed
ur
es

73
78
.2

15
4.
7

39
51
.5

36
.4

SC
vs
.

Re
na
lG
ua
rd

Io
m
ep
ro
l

17
0

3
17
0

C
K
D

un
de
rg
oi
ng

co
ro
na
ry

pr
oc
ed
ur
es

73
78
.2

15
4.
7

39
51
.5

36
.4

SC
vs

Re
na
lG
ua
rd

Io
m
ep
ro
l

17
0

K
on

g
et

al
.

[4
8]

D
efi
ni
tiv

e
or

su
sp
ec
te
d

co
ro
na
ry

ar
te
ry

di
se
as
e

56
.5

53
.8

10
5

23
.8

O
ra
lv

s.
SC

Io
pr
om

id
e

15
2

3
80

D
efi
ni
tiv

e
or

su
sp
ec
te
d

co
ro
na
ry

ar
te
ry

di
se
as
e

56
.5

53
.8

10
5

23
.8

O
ra
lv

s
SC

Io
pr
om

id
e

15
2

K
lim

a
et

al
.

[4
9]

25
8

Re
na
l

in
su
ffi
ci

en
cy

un
de
rg
oi
ng

in
tr
av
as
cu
la
r

co
nt
ra
st

pr
oc
ed
ur
es

77
64

13
7

43
.6

37
44

SC
vs
.S

B
N
ot

m
en
tio

ne
d

10
0

5
25
8

Re
na
l

in
su
ffi
ci
en
cy

un
de
rg
oi
ng

in
tr
av
as
cu
la
r

co
nt
ra
st

pr
oc
ed
ur
es

77
64

13
7

43
.6

37
44

SC
vs

SB
N
ot

m
en
tio

ne
d

10
0

G
om

es
et

al
.

[5
0]

30
1

Pa
tie
nt
s
at

m
od

er
at
e
to

hi
gh

ri
sk

fo
r

de
ve
lo
pi
ng

C
IN

w
ho

w
er
e

re
fe
rr
ed

fo
r

el
ec
tiv

e
C
A
G

PC
I

64
47
.5

13
2.
6

18
.9

SC
vs
.S

B
N
ot

m
en
tio

ne
d

12
5

2
30
1

Pa
tie
nt
s
at

m
od

er
at
e
to

hi
gh

ri
sk

fo
r

de
ve
lo
pi
ng

C
IN

w
ho

w
er
e

re
fe
rr
ed

fo
r

el
ec
tiv

eC
A
G
or

PC
I

64
47
.5

13
2.
6

18
.9

SC
vs

SB
N
ot

m
en
tio

ne
d

12
5

M
ot
oh

ir
o

et
al
.[
51
]

15
5

eG
FR
<6

0
m
l/

m
in
/1
.7
3
m

w
ho

w
er
e

un
de
rg
oi
ng

co
ro
na
ry

an
gi
og
ra
ph

72
.5

69
.7

13
6.
6

44
.3

55
60

SC
vs
.S

B
Io
pa
m
id
ol

13
5

3
15
5

eG
FR
<6

0
m
l/

m
in
/1
.7
3
m

w
ho

w
er
e

un
de
rg
oi
ng

co
ro
na
ry

an
gi
og
ra
ph

72
.5

69
.7

13
6.
6

44
.3

55
60

SC
vs

SB
Io
pa
m
id
ol

13
5

6 Journal of Interventional Cardiology

Ta
bl

e
1:

C
on

tin
ue
d.

St
ud

ie
s

Pa
tie
nt
s

(n
)

In
cl
us
io
n

cr
ite
ri
a/
ri
sk

of
C
I-
A
K
I

M
ea
n

ag
e

(y
ea
rs
)

M
al
es

(%
)

Ba
se
lin

e
SC

r
(m

g/
dL

)

Ba
se
lin

e
eG

FR
(m

L/
m
in
/

1.
73

m
2 )

M
ea
n

LV
EF

(%
)

D
M

(%
)

H
F

(%
)

Tr
ea
tm

en
t

gr
ou

ps
Ty

pe
s
of

C
M

do
sa
ge

(m
L)

Ja
da
d

sc
or
e

N
o.

of
pa
tie
nt
s

In
cl
us
io
n

cr
ite
ri
a/
ri
sk

of
C
I-
A
K
I

M
ea
n

ag
e

M
al
e

(%
)

Ba
se
lin

e
SC

r
Ba

se
lin

e
eG

FR
M
ea
n

LV
EF

D
M

(%
)

H
F

(%
)

G
ro
up

s
Ty

pe
s
of

C
M

D
os
ag
e

of
C
M

Ja
da
d

sc
or
e

M
ai
ol
ie

ta
l.

[5
2]

30
0

ST
EM

I
un

de
rg
oi
ng

pr
im

ar
y
PC

I
65

25
95
.9

42
.5

21
.7

24
N
on

vs
.S

B
Io
di
xa
no

l
21
6

3
30
0

ST
EM

I
un

de
rg
oi
ng

pr
im

ar
y
PC

I
65

25
95
.9

42
.5

21
.7

24
N
on

vs
SB

Io
di
xa
no

l
21
6

Le
e
et

al
.[
53
]

38
2

D
ia
be
tic

pa
tie
nt
s
w
ith

re
na
ld

ise
as
e

(s
er
um

cr
ea
tin

in
e

>1
.1
m
g/
dl

an
d

eG
FR
<6

0
m
l/

m
in
/1
.7
3
m

2 )

68
70
.9

13
2.
6

46
10
0

SC
vs
.S

B
Io
di
xa
no

l
11
6.
5

3
38
2

D
ia
be
tic

pa
tie
nt
s
w
ith

re
na
ld

ise
as
e

(s
er
um

cr
ea
tin

in
e

>1
.1
m
g/
dl

an
d

eG
FR
<6

0
m
l/

m
in
/1
.7
3
m

2 )

68
70
.9

13
2.
6

46
10
0

SC
vs

SB
Io
di
xa
no

l
11
6.
5

H
afi
z
et

al
.

[5
4]

32
0

Pa
tie
nt
s
w
ith

ba
se
lin

e
re
na
l

in
su
ffi
ci
en
cy

sc
he
du

le
d
to

un
de
rg
o

ca
th
et
er
iz
at
io
n

56
.9

14
1.
4

47
.2

SC
vs
.S

B
N
on

io
ni
c,
lo
w

–

os
m
ol
ar

11
5

3
32
0

Pa
tie
nt
s
w
ith

ba
se
lin

e
re
na
l

in
su
ffi
ci
en
cy

sc
he
du

le
d
to

un
de
rg
o

ca
th
et
er
iz
at
io
n

73
56
.9

14
1.
4

47
.2

SC
vs

SB
N
on

io
ni
c,
lo
w
–

os
m
ol
ar

11
5

Br
ig
uo

ri
et

al
.

[5
5]

29
2

H
ig
h-
ri
sk

pa
tie
nt
sw

ith
an

FR
≤3

0
m
l/

m
in
/1
.7
3
m

an
d/
or

a
ri
sk

sc
or
e
≥1

76
65
.4

15
8.
7

32
47

70
.2

28
.4

SB
vs

Re
na
lG
ua
rd

Io
di
xa
no

l
14
0

3
29
2

H
ig
h-
ri
sk

pa
tie
nt
s
w
ith

an
eG

FR
≤3

0
m
l/m

in
/

1.
73

m
2
an
d/
or

a
ri
sk

sc
or
e
≥1

76
65
.4

15
8.
7

32
47

70
.2

28
.4

SB
vs

Re
na
lG
ua
rd

Io
di
xa
no

l
14
0

W
ró
be
le

ta
l.

[5
6]

10
2

C
or
on

ar
y

an
gi
og
ra
ph

y
an
d/
or

an
gi
op

la
st
y,

an
d
ha
d

co
m
or
bi
di
tie
s

th
at

in
cr
ea
se

th
e
ri
sk

of
C
IN

65
.5

56
.9

23
6.
4

O
ra
lv

s.
SC

Lo
ve
rs
ol

69
.5

2
10
2

C
or
on

ar
y

an
gi
og
ra
ph

y
an
d/
or

an
gi
op

la
st
y,

an
d
ha
d

co
m
or
bi
di
tie
s

th
at

in
cr
ea
se

th
e
ri
sk

of
C
IN

65
.5

56
.9

23
6.
4

O
ra
lv

s
SC

Lo
ve
rs
ol

69
.5

V
as
he
gh

an
i-

Fa
ra
ha
ni

et
al
.

[5
7]

C
A
G
,w

ith
SC

r
1.
5
m
g/
dL

w
ith

in
2
w
ee
ks
,

ha
vi
ng

at
le
as
t1

of
th
e
ri
sk

fa
ct
or
s

62
79
.2

15
1.
2

44
.2

36
.1

34
.7

45
.8

0.
45

SC
vs
.

SB
Io
he
xo
l

11
7.
5

3
72

C
A
G
,w

ith
SC

r
1.
5
m
g/
dL

w
ith

in
2
w
ee
ks
,

ha
vi
ng

at
le
as
t1

of
th
e
ri
sk

fa
ct
or
s

62
79
.2

15
1.
2

44
.2

36
.1

34
.7

45
.8

0.
45

SC
vs

SB
Io
he
xo
l

11
7.
5

C
ho

et
al
.[
58
]

U
nd

er
go
in
g

el
ec
tiv

e
C
A
G

78
50
.5

12
3

38
.5

17
.6

SC
vs
.S

B
Is
ov
er
so
l

12
8

2
91

U
nd

er
go
in
g
an

el
ec
tiv

e
C
A
G

78
50
.5

12
3

38
.5

17
.6

SC
vs

SB
Is
ov
er
so
l

12
8

V
as
he
gh

an
i-

Fa
ra
ha
ni

et
al
.

[5
9]

26
5

Se
ru
m

cr
ea
tin

in
e
le
ve
l

of
1.
5
m
g/
dL

or
gr
ea
te
r

un
de
rg
oi
ng

el
ec
tiv

e
C
A
G

63
.3

83
14
5.
4

45
.9

51
.7

21
.5

SC
vs
.S

B
Io
he
xo
l

11
4

5
26
5

Se
ru
m

cr
ea
tin

in
e
le
ve
l

of
1.
5
m
g/
dL

or
gr
ea
te
r

un
de
rg
oi
ng

el
ec
tiv

e
C
A
G

63
.3

83
14
5.
4

45
.9

51
.7

21
.5

SC
vs

SB
Io
he
xo
l

11
4

Ta
m
ur
a
et

al
.

[6
0]

14
4

Sc
he
du

le
d
fo
r

el
ec
tiv

e
C
A
G
or

PC
I

72
.8

87
.5

12
1.
1

39
.1

57
.8

58
.3

SC
vs
.S

B
Io
he
xo
l

85
3

14
4

Sc
he
du

le
d
fo
r

el
ec
tiv

eC
A
G
or

PC
I

72
.8

87
.5

12
1.
1

39
.1

57
.8

58
.3

SC
vs

SB
Io
he
xo
l

85
3

Pa
kf
et
ra
te
ta
l.

[6
1]

19
2

U
nd

er
go
in
g

el
ec
tiv

e
C
A
G
or

PC
I

57
.9

61
.5

97
.2

72
.2

50
.5

29
.7

5.
2

SC
vs
.S

B
Io
di
xa
no

l
65

4
19
2

U
nd

er
go
in
g

el
ec
tiv

eC
A
G
or

PC
I

57
.9

61
.5

97
.2

72
.2

50
.5

29
.7

5.
2

SC
vs

SB
Io
di
xa
no

l
65

H
aa
se

et
al
.

[6
2]

10
0

A
t
in
cr
ea
se
d

ri
sk

of
po

st
op

er
at
iv
e

ac
ut
e
re
na
l

dy
sf
un

ct
io
n

w
ho

w
er
e

sc
he
du

le
d
fo
r

el
ec
tiv

e
or

ur
ge
nt

ca
rd
ia
c

su
rg
er
y

ne
ce
ss
ita

tin
g

th
e
us
e
of

C
PB

71
66

90
.7

SC
vs
.S

B
N
ot

m
en
tio

ne
d

5
10
0

A
t
in
cr
ea
se
d

ri
sk

of
po

st
op

er
at
iv
e

ac
ut
e
re
na
l

dy
sf
un

ct
io
n

w
ho

w
er
e

sc
he
du

le
d
fo
r

el
ec
tiv

e
or

ur
ge
nt

ca
rd
ia
c

su
rg
er
y

ne
ce
ss
ita

tin
g

th
e
us
e
of

C
PB

71
66

90
.7

SC
vs

SB
N
ot

m
en
tio

ne
d

Journal of Interventional Cardiology 7

Ta
bl

e
1:

C
on

tin
ue
d.

St
ud

ie
s

Pa
tie
nt
s

(n
)

In
cl
us
io
n

cr
ite
ri
a/
ri
sk

of
C
I-
A
K
I

M
ea
n

ag
e

(y
ea
rs
)

M
al
es

(%
)

Ba
se
lin

e
SC

r
(m

g/
dL

)

Ba
se
lin

e
eG

FR
(m

L/
m
in
/

1.
73

m
2 )

M
ea
n

LV
EF

(%
)

D
M

(%
)

H
F

(%
)

Tr
ea
tm

en
t

gr
ou

ps
Ty

pe
s
of

C
M

do
sa
ge

(m
L)

Ja
da
d

sc
or
e

N
o.

of
pa
tie
nt
s

In
cl
us
io
n

cr
ite
ri
a/
ri
sk

of
C
I-
A
K
I

M
ea
n

ag
e

M
al
e

(%
)

Ba
se
lin

e
SC

r
Ba

se
lin

e
eG

FR
M
ea
n

LV
EF

D
M

(%
)

H
F

(%
)

G
ro
up

s
Ty

pe
s
of

C
M

D
os
ag
e

of
C
M

Ja
da
d

sc
or
e

Bu
dh

ir
aj
a

et
al
.[
63
]

18
7

N
on

em
er
ge
nt

C
A
G
,b

as
el
in
e

se
ru
m

cr
ea
tin

in
e

>1
.0
m
g/
dL

,
an
d
av
ai
la
bi
lit
y

of
se
ru
m

cr
ea
tin

in
e

va
lu
es

at
da
ys

1–
3

68
12
5.
8

57
.2

30
.5

SC
vs
.S

B
Io
pr
om

id
e

19
9

2
18
7

N
on

em
er
ge
nt

C
A
G
,b

as
el
in
e

se
ru
m

cr
ea
tin

in
e

>1
.0
m
g/
dL

,
an
d
av
ai
la
bi
lit
y

of
se
ru
m

cr
ea
tin

in
e

va
lu
es

at
da
ys

1–
3

68
12
5.
8

57
.2

30
.5

SC
vs

SB
Io
pr
om

id
e

19
9

A
ng

ou
lv
an
t

et
al
.[
64
]

20
1

Sc
he
du

le
d
fo
r

el
ec
tiv

e
C
A
G
,

w
ith

or
w
ith

ou
t

PT
C
A

w
ith

a
ba
se
lin

e
SC

r<
14
0
μm

ol
/

62
80
.6

86
.2

O
ra
lv

s.
SC

N
ot

m
en
tio

ne
d

29
0

3
20
1

Sc
he
du

le
d
fo
r

el
ec
tiv

e
C
A
G
,

w
ith

or
w
ith

ou
t

PT
C
A

w
ith

a
ba
se
lin

e
SC

r<
14
0μ

m
ol
/L

62
80
.6

86
.2

O
ra
lv

s
SC

N
ot

m
en
tio

ne
d

29
0

M
ai
ol
ie

ta
l.

[6
5]

50
2

U
nd

er
go
in
g

co
ro
na
ry

an
gi
og
ra
ph

pr
oc
ed
ur
es
w
ith

es
tim

at
ed

cr
ea
tin

in
e

cl
ea
ra
nc
e

<6
0
m
l/m

74
59

10
7

46
.5

59
.1

SC
vs
.S

B
Io
di
xa
no

l
16
5

3
50
2

U
nd

er
go
in
g

co
ro
na
ry

an
gi
og
ra
ph

ic
pr
oc
ed
ur
es

w
ith

es
tim

at
ed

cr
ea
tin

in
e

cl
ea
ra
nc
e

<6
0
m
l/m

74
59

10
7

46
.5

59
.1

SC
vs

SB
Io
di
xa
no

l
16
5

C
he
n
et

al
.

[6
6]

66
0

M
yo
ca
rd
ia
l

isc
he
m
ia

(a
ng

in
a
or

po
sit
iv
e

ex
er
ci
se

tr
ea
dm

ill
)

sc
he
du

le
d
fo
r

PC
I,
w
ith

SC
r<

1.
5
m
g/
dl

60
85

11
4.
9

54
8

N
on

vs
.S

C
Is
o-
os
m
ol
ar

no
ni
on

ic
28
5

2
66
0

M
yo
ca
rd
ia
l

isc
he
m
ia

(a
ng

in
a
or

po
sit
iv
e

ex
er
ci
se

tr
ea
dm

ill
)

sc
he
du

le
d
fo
r

PC
I,
w
ith

SC
r<

1.
5
m
g/
dl

60
85

11
4.
9

54
8

N
on

vs
SC

Is
o-
os
m
ol
ar

no
ni
on

ic
28
5

C
he
n
et

al
.

[6
6]

27
6

M
yo
ca
rd
ia
l

isc
he
m
ia

(a
ng

in
a
or

po
sit
iv
e

ex
er
ci
se

tr
ea
dm

ill
)

sc
he
du

le
d
fo
r

PC
I,
w
ith

SC
r≥

1.
5
m
g/
dl

63
82

22
1

41
22

N
on

vs
.S

C
Is
o-
os
m
ol
ar

no
ni
on

ic
29
8

2
27
6

M
yo
ca
rd
ia
l

isc
he
m
ia

(a
ng

in
a
or

po
sit
iv
e

ex
er
ci
se

tr
ea
dm

ill
)

sc
he
du

le
d
fo
r

PC
I,
w
ith

SC
r≥

1.
5
m
g/
dl

63
82

22
1

41
22

N
on

vs
SC

Is
o-
os
m
ol
ar

no
ni
on

ic
29
8

Br
ar

et
al
.[
67
]

35
3

Pa
tie
nt
s
w
ith

st
ab
le

re
na
l

di
se
as
e
an
d

un
de
rg
oi
ng

C
A
G

71
63
.9

13
1.
7

48
57

44
.5

27
.2

SC
vs
.S

B
Io
xi
la
n

13
2

5
35
3

Pa
tie
nt
s
w
ith

st
ab
le

re
na
l

di
se
as
e
an
d

un
de
rg
oi
ng

C
A
G

71
63
.9

13
1.
7

48
57

44
.5

27
.2

SC
vs

SB
Io
xi
la
n

13
2

A
do

lp
h
et

al
.

[6
8]

14
5

St
ab
le

re
na
l

in
su
ffi
ci
en
cy

an
d
un

de
rg
oi
ng

el
ec
tiv

e
di
ag
no

st
ic

or
in
te
rv
en
tio

na
l

co
ro
na
ry

an
gi
og
ra
ph

72
.6

77
.9

13
2.
6

33
.8

SC
vs
.S

B
Io
di
xa
no

l
14
0

5
14
5

St
ab
le

re
na
l

in
su
ffi
ci
en
cy

an
d

un
de
rg
oi
ng

el
ec
tiv

e
di
ag
no

st
ic

or
in
te
rv
en
tio

na
l

co
ro
na
ry

an
gi
og
ra
ph

72
.6

77
.9

13
2.
6

33
.8

SC
vs

SB
Io
di
xa
no

l
14
0

Sc
hm

id
te

t
al
.

[6
9]

96
C
A
G

67
.6

74
14
6.
7

64
.6

SC
vs
.S

B
O
pt
ir
ay

18
6

2
96

C
A
G

67
.6

74
14
6.
7

64
.6

SC
vs

SB
O
pt
ir
ay

18
6

O
zc
an

et
al
.

[7
0]

26
4

Sc
he
du

le
d
fo
r

C
A
G

or
PC

I
an
d
ha
d
a

ba
se
lin

e
cr
ea
tin

in
e
le
ve
l

>1
.2
m
g/
dL

69
74
.6

12
2.
9

45
.1

26
.5

SC
vs
.S

B
Io
xa
gl
at
e

11
0

2
26
4

Sc
he
du

le
d
fo
r

C
A
G

or
PC

I
an
d
ha
d
a

ba
se
lin

e
cr
ea
tin

in
e
le
ve
l

>1
.2
m
g/
dL

69
74
.6

12
2.
9

45
.1

26
.5

SC
vs

SB
Io
xa
gl
at
e

11
0

8 Journal of Interventional Cardiology

Ta
bl

e
1:

C
on

tin
ue
d.

St
ud

ie
s

Pa
tie
nt
s

(n
)

In
cl
us
io
n

cr
ite
ri
a/
ri
sk

of
C
I-
A
K
I

M
ea
n

ag
e

(y
ea
rs
)

M
al
es

(%
)

Ba
se
lin

e
SC

r
(m

g/
dL

)

Ba
se
lin

e
eG

FR
(m

L/
m
in
/

1.
73

m
2 )

M
ea
n

LV
EF

(%
)

D
M

(%
)

H
F

(%
)

Tr
ea
tm

en
t

gr
ou

ps
Ty

pe
s
of

C
M

do
sa
ge

(m
L)

Ja
da
d

sc
or
e

N
o.

of
pa
tie
nt
s

In
cl
us
io
n

cr
ite
ri
a/
ri
sk

of
C
I-
A
K
I

M
ea
n

ag
e

M
al
e

(%
)

Ba
se
lin

e
SC

r
Ba

se
lin

e
eG

FR
M
ea
n

LV
EF

D
M

(%
)

H
F

(%
)

G
ro
up

s
Ty

pe
s
of

C
M

D
os
ag
e

of
C
M

Ja
da
d

sc
or
e

M
as
ud

a
et

al
.

[7
1]

Sc
he
du

le
d
to

un
de
rg
o
an

em
er
ge
nc
y

co
ro
na
ry

an
gi
og
ra
ph

y
or

in
te
rv
en
tio

75
44
.1

11
6.
2

30
.5

SC
vs
.S

B
Io
pa
m
id
ol

11
6

3
59

Sc
he
du

le
d
to

un
de
rg
o
an

em
er
ge
nc
y

co
ro
na
ry

an
gi
og
ra
ph

y
or

in
te
rv
en
tio

75
44
.1

11
6.
2

30
.5

SC
vs

SB
Io
pa
m
id
ol

11
6

D
us
so
le

t
al
.

[7
2]

15
6

C
K
D
,w

ho
w
er
e

un
de
rg
oi
ng

ra
di
ol
og
ic
al

pr
oc
ed
ur
es
w
ith

C
M

67
.9

20
4.
5

33
.1

28
.8

16
SC

vs
.

SC
+
di
ur
es
is

N
on

io
ni
c,
lo
w

os
m
ol
ar

11
7

5
15
6

C
K
D
,w

ho
w
er
e

un
de
rg
oi
ng

ra
di
ol
og
ic
al

pr
oc
ed
ur
es

w
ith

C
M

65
67
.9

20
4.
5

33
.1

28
.8

16
SC

vs
SC

+
di
ur
es
is

N
on

io
ni
c,
lo
w

os
m
ol
ar

11
7

M
ue
lle
r
et

al
.

[7
3]

42
5

Sc
he
du

le
d
fo
r

el
ec
tiv

e
or

em
er
ge
nc
y
PC

I
64

75
89

16
0.
45

SC
vs
.

SC
Io
pr
om

id
e

22
6

2
42
5

Sc
he
du

le
d
fo
r

el
ec
tiv

e
or

em
er
ge
nc
y
PC

I
64

75
89

16
0.
45

SC
vs

SC
Io
pr
om

id
e

22
6

M
er
te
n
et

al
.

[7
4]

11
9

St
ab
le

re
na
l

in
su
ffi
ci
en
cy

un
de
rg
oi
ng

di
ag
no

st
ic

or
in
te
rv
en
tio

na
l

pr
oc
ed
ur
es

re
qu

ir
in
g

ra
di
og
ra
ph

ic
co
nt
ra
st
,S

C
r>

1.
1
m
g/
dL

68
74
.8

15
9.
1

47
.9

SC
vs
.S

B
Io
pa
m
id
ol

13
2

3
11
9

St
ab
le

re
na
l

in
su
ffi
ci
en
cy

un
de
rg
oi
ng

di
ag
no

st
ic

or
in
te
rv
en
tio

na
l

pr
oc
ed
ur
es

re
qu

ir
in
g

ra
di
og
ra
ph

ic
co
nt
ra
st
,S

C
r>

1.
1
m
g/
dL

68
74
.8

15
9.
1

47
.9

SC
vs

SB
Io
pa
m
id
ol

13
2

Tr
iv
ed
ie

ta
l.

[7
5]

Sc
he
du

le
d
to

un
de
rg
o

no
ne
m
er
ge
nc
y

C
A
G

67
.9

98
.1

10
6.
4

52
.1

18
.9

O
ra
lv

s.
SC

Io
ni
c,
lo
w
–

os
m
ol
ar

14
8

2
53

Sc
he
du

le
d
to

un
de
rg
o

no
ne
m
er
ge
nc
y

C
A
G

67
.9

98
.1

10
6.
4

52
.1

18
.9

O
ra
lv

s
SC

Io
ni
c,
lo
w
–

os
m
ol
ar

14
8

M
ue
lle
r
et

al
.

[7
6]

13
83

Sc
he
du

le
d
fo
r

el
ec
tiv

e
or

em
er
ge
nc
y

C
A
G

64
74
.4

81
.7
7

15
.7

0.
45

SC
vs
.

SC
U
ltr
av
ist

or
im

er
on

23
4

2
13
83

Sc
he
du

le
d
fo
r

el
ec
tiv

e
or

em
er
ge
nc
y

C
A
G

64
74
.4

81
.7
7

15
.7

0.
45

SC
vs

SC
U
ltr
av
ist
,o

r
im

er
on

23
4

C
I-
A
K
I:
co
nt
ra
st
-in

du
ce
d
ac
ut
e
ki
dn

ey
in
ju
ry
;S

C
r:
se
ru
m

cr
ea
tin

in
e;
eG

FR
:e
st
im

at
ed

gl
om

er
ul
ar

fil
tr
at
io
n
ra
te
;L

V
EF

:l
ef
tv

en
tr
ic
ul
ar

ej
ec
tio

n
fr
ac
tio

n;
D
M
:d

ia
be
te
s
m
el
lit
us
;H

F:
he
ar
tf
ai
lu

re
;C

M
:c
on

tr
as
t

m
ed
ia
;C

A
:c

te
d

to
m
og
ra
ph

y
an
gi
og
ra
ph

y;
TA

V
I:
tr
an
sc
at
he
te
ra

or
tic

va
lv
e
im

pl
an
ta
tio

n;
EV

A
R:

el
ec
tiv

e
en
do

va
sc
ul
ar

an
eu
ry
sm

re
pa
ir
;A

A
A
:a
bd

om
in
al
ao
rt
ic
an
eu
ry
sm

;C
K
D
:c
hr
on

ic
ki
dn

ey
di
se
as
e;

C
RT

:c
ar
di
ac

re
sy
nc
hr
on

iz
at
io
n
th
er
ap
y;

C
TP

A
:c

om
pu

te
d
to
m
og
ra
ph

y
pu

lm
on

ar
y
an
gi
og
ra
ph

y;
PE

:p
ul
m
on

ar
y
em

bo
lis
m
;C

IN
:c

on
tr
as
t-
in
du

ce
d
ne
ph

ro
pa
th
y;

C
H
F:

ch
ro
ni
c
he
ar
t
fa
ilu

re
;C

T:
co
m
pu

te
d

to
m
og
ra
ph

y;
TA

V
R:

tr
an
sc
at
he
te
r
ao
rt
ic

va
lv
e
re
pl
ac
em

en
t;
C
A
G
:
co
ro
na
ry

an
gi
og
ra
ph

y;
C
E-
C
T:

co
nt
ra
st

m
ed
ia
-e
nh

an
ce
d
co
m
pu

te
d
to
m
og
ra
ph

y;
C
PB

:
ca
rd
io
pu

lm
on

ar
y
by
pa
ss
;
PT

C
A
:
pe
rc
ut
an
eo
us

tr
an
slu

m
in
al
co
ro
na
ry

an
gi
op

la
st
y;
N
A
C
:N

-a
ce
ty
lc
ys
te
in
e.
Tr
ea
tm

en
tg

ro
up

s:
SC

:i
nt
ra
ve
no

s
0.
9%

so
di
um

ch
lo
ri
de

;S
B:

in
tr
av
en
ou

ss
od

iu
m

bi
ca
rb
on

at
e;
N
on

:n
on

hy
dr
at
io
n;

O
ra
l:
or
al
hy
dr
at
io
n;

Re
na
lG
ua
rd
:

Re
na
lG
ua
rd

sy
st
em

;H
D
y:

he
m
od

yn
am

ic
gu
id
ed

hy
dr
at
io
n;

SC
+
di
ur
es
is:

in
tr
av
en
ou

s
0.
9%

so
di
um

ch
lo
ri
de

+
di
ur
es
is;

0.
45

SC
:0

.4
5%

so
di
um

ch
lo
ri
de
.

Journal of Interventional Cardiology 9

influential studies concluded that intravenous sodium bi-
carbonate provided no benefit over intravenous sodium
chloride in high-risk patients [11] and critically ill patients
[12]. Our NMA included 37 studies that compared intra-
venous sodium chloride with sodium bicarbonate, and our
results also indicated that intravenous sodium bicarbonate
led to a reduced risk for CI-AKI, although the effect size was
small (OR [95% CI]: 0.74 [0.57, 0.93]). Alkalization with
bicarbonate perfusion could theoretically reduce the for-
mation of reactive oxygen species by decreasing the
production of hydroxyl radicals due to inhibition of the
Haber-Weiss and Fenton reactions [84]. However, the
HYDRAREA study [12] assessed 307 critically ill patients
with stable renal function and found that hydration with
bicarbonate provided no benefit relative to hydration with
isotonic sodium chloride. -ese researchers also noted
that bicarbonate provided a greater benefit in the smaller
studies, suggesting publication bias. Recently, Weisbord
et al. [11] enrolled 5177 patients with high risk for renal
complications and found that administration of sodium
bicarbonate did not reduce the occurrence of CI-AKI.-is
result supports the interpretation that sodium bicarbonate
is not more effective than sodium chloride in preventing
CI-AKI or longer-term adverse outcomes after angiog-
raphy. However, there was high heterogeneity among our
60 studies regarding concurrent medications, comor-
bidities (CHF, DM), types of CM, periprocedural hy-
dration protocols, concentrations and dosages of sodium
bicarbonate, and radiographic procedures [12]. -us, we

do not recommend alkalization with intravenous sodium
bicarbonate as a single strategy, and a more effective
hydration strategy is needed to prevent CI-AKI.

Several recent RCTs of high risk patients [13, 28, 47, 55]
showed that furosemide-induced high-volume forced di-
uresis with matched hydration using the RenalGuard system
effectively prevented CI-AKI. RenalGuard is a closed-loop
fluid-management system, in which each volume of urine
that enters the collection bag leads to the infusion of an equal
volume of saline into the patient. Two meta-analyses [14, 16]
of RCTs concluded that the RenalGuard system signifi-
cantly reduced the risk of CI-AKI and the need for renal
replacement therapy in high-risk patients undergoing
coronary angiography. Our rankogram analysis indicated
that the RenalGuard system of guided hydration had the
highest rank, with a SUCRA of 0.974. However, we did not
assess the effectiveness of intravenous hydration plus di-
uresis without a guided system, and the rankogram indi-
cated that hemodynamic guided hydration was the second
best method, with a SUCRA of 0.849. Brar et al. [17] used
left ventricular end-diastolic pressure to guide fluid ad-
ministration and demonstrated that this method was safe
and effective in prevention of CI-AKI among patients
undergoing cardiac catheterization. Another study [19]
demonstrated that central venous pressure-guided fluid
administration safely and effectively reduced the risk of CI-
AKI in patients with CKD and CHF. Maioli et al. [18]
assessed body fluid level using bioimpedance vector
analysis (BIVA), which allows adjustment of intravascular

Nonhydration

Oral hydration

Half isotonic
sodium chloride

Intravenous
sodium chloride

Intravenous
sodium bicarbonate

Intravenous hyration
+ diuresis

Hemodynamic-guided
hydration

RenalGuard guided
hydration

37 studies

6
stu

di
es

3 s
tudie

1 study

1 study 5 s
tu

di
es

3 studies

3 stu
dies

2 studies

1 study

2 studies

Figure 2: Network diagram of eight hydration strategies used to prevent contrast-induced acute kidney injury in the 60 included studies.
Circles represent hydration strategies and lines represent direct comparisons. Circle size indicates the number of participants who received
each treatment, and line thickness indicates the number of studies in each comparison.

10 Journal of Interventional Cardiology

0.01 0.1 1 10

IV SB versus IV SC 0.86 (0.77–0.96)
0.98 (0.34–2.57)

IV SC versus oral hydration 0.86 (0.49–1.50)
0.91 (0.27–3.32)

IV + diuresis versus IV SB 0.80 (0.52–1.20)
0.89 (0.42–1.93)

IV SB versus oral hydration 0.74 (0.42–1.31)
0.74 (0.57–0.93)

IV + diuresis versus IV SC 0.68 (0.46–1.02)
0.72 (0.28–1.82)

RenalGuard versus
hemodynamic guided

0.68 (0.36–1.28)
0.72 (0.24–1.94)

Oral hydration versus no
hydration

0.66 (0.36–1.22)
0.66 (0.22–2.15)

Hemodynamic guided versus
IV + diuresis

0.61 (0.34–1.09)
0.65 (0.29–1.46)

IV + diuresis versus oral
hydration

0.59 (0.29–1.16)
0.64 (0.39–1.08)

No hydration versus half SC 0.57 (0.22–1.34)
0.58 (0.18–1.79)

IV SC versus no hydration 0.56 (0.45–0.72)
0.56 (0.24–1.33)

IV SB versus no hydration 0.48 (0.38–0.62)
0.50 (0.13–1.76)

Hemodynamic guided versus IV
SB

0.48 (0.31–0.74)
0.47 (0.28–0.81)

Hemodynamic guided versus IV
SC

0.42 (0.27–0.63)
0.41 (0.18–0.93)

RenalGuard versus IV + diuresis 0.41 (0.22–0.77)
0.40 (0.11–1.43)

IV + diuresis versus no hydration 0.39 (0.24–0.61)
0.36 (0.12–1.13)

Oral hydration versus half SC 0.38 (0.13–1.03)
0.36 (0.08–1.42)

Hemodynamic guided versus
oral hydration

0.36 (0.18–0.71)
0.33 (0.07–1.57)

RenalGuard versus IV SB 0.33 (0.20–0.53)
0.32 (0.14–0.70)

IV SC versus half SC 0.32 (0.13–0.73)
0.32 (0.09–1.02)

RenalGuard versus IV SC 0.28 (0.17–0.45)
0.26 (0.10–0.70)

IV SB versus half SC 0.28 (0.11–0.63)
0.24 (0.10–0.51)

RenalGuard versus oral
hydration

0.24 (0.12–0.50)
0.23 (0.07–0.75)

Hemodynamic guided versus no
hydration

0.23 (0.14–0.38)
0.23 (0.06–0.80)

IV + diuresis versus half SC 0.22 (0.08–0.55)
0.21 (0.07–0.63)

RenalGuard versus no hydration 0.16 (0.09–0.27)
0.15 (0.06–0.38)

Hemodynamic guided versus
half SC

0.13 (0.05–0.34)
0.13 (0.03–0.54)

RenalGuard versus half SC 0.09 (0.03–0.24)
0.07 (0.02–0.30)

Treatment 1 vs. treatment 2 O.R. (95% Cr.I.)

Favours treatment 1 Favours treatment 2Heterogeneity (vague) = 0.5817
95% CrI (0.3711–0.8451)

Fixed effects

Random effects (vague prior)

Figure 3: Forest plot showing the effect of different hydration strategies. Summary estimates from the pooled studies with 95% confidence
intervals are indicated for fixed effects (open diamonds) and random effects (filled diamonds) models.

Journal of Interventional Cardiology 11

volume expansion, and this led to a lower incidence of CI-
AKI after angiographic procedures. -erefore, our results
indicate that the RenalGuard system and hemodynamic
guided hydration are best for patients with high-risk for CI-
AKI, especially those with CKD and cardiac dysfunction.

5. Limitations

It is essential to note several limitations of our study.
Firstly, the hydration protocol should have a substantial

influence on CI-AKI, but because of the high heteroge-
neity of specific protocols used in the included studies, we
could not analyze distinct protocols, such as the effect of
different concentrations of sodium bicarbonate, and the
effect of hydration duration. Secondly, several con-
founding factors that we did consider may have impacted
the effects of hydration, including dosage and types of
CM, risk status of patients for CI-AKI, and other factors.
Finally, it may be inappropriate to define hemodynamic
guided hydration based on the use of different indexes,
such as left ventricular end-diastolic pressure, central
venous pressure, and bioimpedance.

6. Conclusion

-is Bayesian NMA provided substantial evidence to sup-
port the use of RenalGuard or hemodynamic guided hy-
dration to prevent CI-AKI in high-risk patients, especially
those with CKD or cardiac dysfunction.

OR <1 means the treatment in top le� is better

RenalGuard

0.58
(0.18–1.79)

Hemodynamic
guided

0.32
(0.14–0.70)

0.56
(0.24–1.33) IV SB

0.24
(0.10–0.51)

0.41
(0.18–0.93)

0.74
(0.57–0.93) IV SC

0.23
(0.06–0.80)

0.40
(0.11–1.43)

0.72
(0.24–1.94)

0.98
(0.34–2.57) IV + diuresis

0.21
(0.07–0.63)

0.36
(0.12–1.13)

0.65
(0.29–1.46)

0.89
(0.42–1.93)

0.91
(0.27–3.32) Oral hydration

0.15
(0.06–0.38)

0.26
(0.10–0.70)

0.47
(0.28–0.81)

0.64
(0.39–1.08)

0.66
(0.22–2.15)

0.72
(0.28–1.82) No hydration

0.07
(0.02–0.30)

0.13
(0.03–0.54)

0.23
(0.07–0.75)

0.32
(0.09–1.02)

0.33
(0.07–1.57)

0.36
(0.08–1.42)

0.50
(0.13–1.76) Half SC

Figure 4: League table, showing all pairwise comparisons of studies.

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1 2 3 4 5 6 7 8

Pr
ob

ab
ili

ty
o

f b
ei

ng
ra

nk
ed

Rank

Random effects (vague) rankogram

RenalGuard
Hemodynamic-guided
IV + diuresis
IV SB

IV SC
Half SC
Oral hydration
No hydration

Best Worst

Figure 5: Rankogram of the effect of different hydration strategies
in reducing the risk of contrast-induced acute kidney injury.

0.5

1.5

0 0.5 1 1.5 2

In
co

ns
ist

en
cy

m
od

Consistency model

Fixed effects

Martin-Moreno PL 2015

Nijssen EC 2017

Figure 6: Inconsistency plot of enrolled studies, showing the
posterior mean deviance of each study from the consistency
model (horizontal axis) and the inconsistency model (vertical
axis).

12 Journal of Interventional Cardiology

Abbreviations

CI-
AKI:

Contrast-induced acute kidney injury

SCr: Serum creatinine
eGFR: Estimated glomerular filtration rate
LVEF: Left ventricular ejection fraction
DM: Diabetes mellitus
HF: Heart failure
CM: Contrast medium
CTA: Computed tomography angiography
TAVI: Transcatheter aortic valve implantation
EVAR: Elective endovascular aneurysm repair
AAA: Abdominal aortic aneurysm
CKD: Chronic kidney disease
CRT: Cardiac resynchronization therapy
CTPA: Computed tomography pulmonary angiography
PE: Pulmonary embolism
CIN: Contrast-induced nephropathy
CHF: Chronic heart failure
CT: Computed tomography
TAVR: Transcatheter aortic valve replacement
CAG: Coronary angiography
CE-CT: Contrast media-enhanced computed tomography
CPB: Cardiopulmonary bypass
PTCA: Percutaneous transluminal coronary angioplasty.

Conflicts of Interest

All authors have no conflicts of interest and no relationships
with industry.

Authors’ Contributions

Qiuping Cai and Ran Jing contributed equally to this paper.
C. Q. P. and J. R. carried out meta-analysis, participated in
data extraction, and drafted manuscript. Z.W. F. and T. Y. S.
carried out quality assessment. L. X. P. participated in study
design and performed statistical analysis. L. T. Q. conceived
the study and participated in its design and coordination and
helped to draft the manuscript. All authors read and ap-
proved the final manuscript.

Acknowledgments

-is work was supported by grants from the National
Natural Science Foundation of China (81670627),
Changzhou Health and Family Planning CommissionMajor
Sci and Tech Projects of China (ZD201501), Changzhou
Health and Family Planning Commission Youth Founda-
tion of China (QN201814), and Changzhou Sci and Tech
Program of China (CJ20159042).

References

[1] T. G. Gleeson and S. Bulugahapitiya, “Contrast-induced
nephropathy,” American Journal of Roentgenology, vol. 183,
no. 6, pp. 1673–1689, 2004.

[2] C. S. Rihal, S. C. Textor, D. E. Grill et al., “Incidence and
prognostic importance of acute renal failure after

percutaneous coronary intervention,” Circulation, vol. 105,
no. 19, pp. 2259–2264, 2002.

[3] P. A. McCullough, R. Wolyn, L. L. Rocher, R. N. Levin, and
W. W. O’Neill, “Acute renal failure after coronary inter-
vention: incidence, risk factors, and relationship to mortality,”
�e American Journal of Medicine, vol. 103, no. 5, pp. 368–
375, 1997.

[4] H. S. -omsen and S. K. Morcos, “Contrast media and the
kidney: European Society of Urogenital Radiology (ESUR)
guidelines,” �e British Journal of Radiology, vol. 76, no. 908,
pp. 513–518, 2003.

[5] J. A. Kellum, N. Lameire, P. Aspelin et al., “Kidney disease:
improving global outcomes (KDIGO) acute kidney injury
work group. KDIGO clinical practice guideline for acute
kidney injury,” Kidney International Supplements, vol. 2,
pp. 1–138, 2012.

[6] W. Zhang, J. Zhang, B. Yang et al., “Effectiveness of oral
hydration in preventing contrast-induced acute kidney injury
in patients undergoing coronary angiography or intervention:
a pairwise and network meta-analysis,” Coronary Artery
Disease, vol. 29, no. 4, pp. 286–293, 2018.

[7] Y. Jiang, M. Chen, Y. Zhang et al., “Meta-analysis of pro-
phylactic hydration versus no hydration on contrast-induced
acute kidney injury,” Coronary Artery Disease, vol. 28, no. 8,
pp. 649–657, 2017.

[8] S. K. Agarwal, S. Mohareb, A. Patel et al., “Systematic oral
hydration with water is similar to parenteral hydration for
prevention of contrast-induced nephropathy: an updated
meta-analysis of randomised clinical data,”Open Heart, vol. 2,
Article ID e000317, 2015.

[9] S. Zoungas, T. Ninomiya, R. Huxley et al., “Systematic review:
sodium bicarbonate treatment regimens for the prevention of
contrast-induced nephropathy,” Annals of Internal Medicine,
vol. 151, no. 9, pp. 631–638, 2009.

[10] E. C. Nijssen, R. J. Rennenberg, P. J. Nelemans et al., “Pro-
phylactic hydration to protect renal function from intravas-
cular iodinated contrast material in patients at high risk of
contrast-induced nephropathy (AMACING): a prospective,
randomised, phase 3, controlled, open-label, non-inferiority
trial,” �e Lancet, vol. 389, no. 10076, pp. 1312–1322, 2017.

[11] S. D. Weisbord, M. Gallagher, H. Jneid et al., “Outcomes after
angiography with sodium bicarbonate and acetylcysteine,”
New England Journal of Medicine, vol. 378, no. 7, pp. 603–614,
2018.

[12] X. Valette, I. Desmeulles, B. Savary et al., “Sodium bicarbonate
versus sodium chloride for preventing contrast-associated
acute kidney injury in critically ill patients: a randomized
controlled trial,” Critical Care Medicine, vol. 45, no. 4,
pp. 637–644, 2017.

[13] M. Barbanti, S. Gulino, P. Capranzano et al., “Acute kidney
injury with the RenalGuard system in patients undergoing
transcatheter aortic valve replacement: the PROTECT-TAVI
trial (PROphylactic effecT of furosEmide-induCed diuresis
with matched isotonic intravenous hydraTion in transcatheter
aortic valve implantation),” JACC: Cardiovascular Interven-
tions, vol. 8, no. 12, pp. 1595–1604, 2015.

[14] A. Putzu, M. Boscolo Berto, A. Belletti et al., “Prevention of
contrast-induced acute kidney injury by furosemide with
matched hydration in patients undergoing interventional
procedures: a systematic review and meta-analysis of ran-
domized trials,” JACC: Cardiovascular Interventions, vol. 10,
no. 4, pp. 355–363, 2017.

[15] G. Visconti, A. Focaccio, M. Donahue et al., “RenalGuard
system for the prevention of acute kidney injury in patients

Journal of Interventional Cardiology 13

undergoing transcatheter aortic valve implantation,” Euro-
Intervention, vol. 11, no. 14, pp. e1658–e1661, 2016.

[16] R. Shah, S. J.Wood, S. A. Khan, A. Chaudhry, M. Rehan Khan,
and M. S. Morsy, “High-volume forced diuresis with matched
hydration using the RenalGuard system to prevent contrast-
induced nephropathy: a meta-analysis of randomized trials,”
Clinical Cardiology, vol. 40, no. 12, pp. 1242–1246, 2017.

[17] S. S. Brar, V. Aharonian, P. Mansukhani et al., “Haemody-
namic-guided fluid administration for the prevention of
contrast-induced acute kidney injury: the POSEIDON
randomised controlled trial,” �e Lancet, vol. 383, no. 9931,
pp. 1814–1823, 2014.

[18] M. Maioli, A. Toso, M. Leoncini et al., “Bioimpedance-guided
hydration for the prevention of contrast-induced kidney
injury: the HYDRA study,” Journal of the American College of
Cardiology, vol. 71, no. 25, pp. 2880–2889, 2018.

[19] G. Qian, Z. Fu, J. Guo, F. Cao, and Y. Chen, “Prevention of
contrast-induced nephropathy by central venous pressure-
guided fluid administration in chronic kidney disease and
congestive heart failure patients,” JACC: Cardiovascular In-
terventions, vol. 9, no. 1, pp. 89–96, 2016.

[20] J. Higgins and S. Green, Cochrane Handbook for Systematic
Reviews of Interventions, -e Cochrane Collaboration, Lon-
don, UK, 2011.

[21] A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the
quality of reports of randomized clinical trials: is blinding
necessary?,” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12,
1996.

[22] A. E. Ades, M. Sculpher, A. Sutton et al., “Bayesian methods
for evidence synthesis in cost-effectiveness analysis,” Phar-
macoEconomics, vol. 24, no. 1, pp. 1–19, 2006.

[23] S. Brown, B. Hutton, T. Clifford et al., “A microsoft-excel-
based tool for running and critically appraising network
meta-analyses–an overview and application of NetMetaXL,”
Systematic Reviews, vol. 3, p. 110, 2014.

[24] M. S. van Mourik, F. van Kesteren, R. N. Planken et al., “Short
versus conventional hydration for prevention of kidney injury
during pre-TAVI computed tomography angiography,”
Netherlands Heart Journal, vol. 26, no. 9, pp. 425–432, 2018.

[25] A. Saratzis, V. Chiocchia, A. Jiffry et al., “HYDration and
bicarbonate to prevent acute renal injury after endovascular
aneurysm repair with suprarenal fixation: pilot/feasibility
randomised controlled study (HYDRA pilot trial),” European
Journal of Vascular and Endovascular Surgery, vol. 55, no. 5,
pp. 648–656, 2018.

[26] J. Kooiman, J. P. M. de Vries, J. Van der Heyden et al.,
“Randomized trial of one-hour sodium bicarbonate vs stan-
dard periprocedural saline hydration in chronic kidney dis-
ease patients undergoing cardiovascular contrast procedures,”
PLoS One, vol. 13, Article ID e0189372, 2018.

[27] P. Alonso, J. Sanz, A. Garćıa-Orts et al., “Usefulness of sodium
bicarbonate for the prevention of contrast-induced ne-
phropathy in patients undergoing cardiac resynchronization
therapy,” �e American Journal of Cardiology, vol. 120, no. 9,
pp. 1584–1588, 2017.

[28] T. Usmiani, A. Andreis, C. Budano et al., “AKIGUARD (acute
kidney injury GUARding device) trial: in-hospital and one-
year outcomes,” Journal of Cardiovascular Medicine, vol. 17,
no. 7, pp. 530–537, 2016.

[29] S. Turedi, E. Erdem, Y. Karaca et al., “-e high risk of contrast-
induced nephropathy in patients with suspected pulmonary
embolism despite three different prophylaxis: a randomized
controlled trial,” Academic Emergency Medicine, vol. 23,
no. 10, pp. 1136–1145, 2016.

[30] R. Solomon, P. Gordon, S. V. Manoukian et al., “Randomized
trial of bicarbonate or saline study for the prevention of
contrast-induced nephropathy in patients with CKD,” Clin-
ical Journal of the American Society of Nephrology, vol. 10,
no. 9, pp. 1519–1524, 2015.

[31] P. L. Martin-Moreno, N. Varo, E. Mart́ınez-Ansó et al.,
“Comparison of intravenous and oral hydration in the pre-
vention of contrast-induced acute kidney injury in low-risk
patients: a randomized trial,” Nephron, vol. 131, no. 1,
pp. 51–58, 2015.

[32] A. Jurado-Román, F. Hernández-Hernández, J. Garcı́a-Tejada
et al., “Role of hydration in contrast-induced nephropathy in
patients who underwent primary percutaneous coronary
intervention,” �e American Journal of Cardiology, vol. 115,
no. 9, pp. 1174–1178, 2015.

[33] M. R. Yeganehkhah, L. Iranirad, F. Dorri et al., “Comparison
between three supportive treatments for prevention of con-
trast-induced nephropathy in high-risk patients undergoing
coronary angiography,” Saudi Journal of Kidney Diseases and
Transplantation: An Official Publication of the Saudi Center
for Organ Transplantation, Saudi Arabia, vol. 25, no. 25,
pp. 1217–1223, 2014.

[34] K. Yang,W. Liu,W. Ren, and S. Lv, “Different interventions in
preventing contrast-induced nephropathy after percutaneous
coronary intervention,” International Urology and Nephrol-
ogy, vol. 46, no. 9, pp. 1801–1807, 2014.

[35] P. -ayssen, J. F. Lassen, S. E. Jensen et al., “Prevention of
contrast-induced nephropathy with N-acetylcysteine or so-
dium bicarbonate in patients with ST-segment-myocardial
infarction: a prospective, randomized, open-labeled trial,”
Circulation: Cardiovascular Interventions, vol. 7, no. 2,
pp. 216–224, 2014.

[36] J. F. Nieto-Rios, W. A. Salazar, O. M. Sanchez et al., “Pre-
vention of contrast induced nephropathy with sodium bi-
carbonate (the PROMEC study),” Jornal Brasileiro de
Nefrologia, vol. 36, pp. 360–366, 2014.

[37] A. Manari, P. Magnavacchi, E. Puggioni et al., “Acute kidney
injury after primary angioplasty: effect of different hydration
treatments,” Journal of Cardiovascular Medicine, vol. 15, no. 1,
pp. 60–67, 2014.

[38] K. Mahmoodi, B. Sohrabi, F. Ilkhchooyi, M. Malaki,
M. E. Khaniani, and M. Hemmati, “-e efficacy of hydration
with normal saline versus hydration with sodium bicarbonate
in the prevention of contrast-induced nephropathy,” Heart
Views: �e Official Journal of the Gulf Heart Association,
vol. 15, no. 15, pp. 33–36, 2014.

[39] Y. Luo, X.Wang, Z. Ye et al., “Remedial hydration reduces the
incidence of contrast-induced nephropathy and short-term
adverse events in patients with ST-segment elevation myo-
cardial infarction: a single-center, randomized trial,” Internal
Medicine, vol. 53, no. 20, pp. 2265–2272, 2014.

[40] J. Kooiman, Y. W. J. Sijpkens, J.-P. P. M. de Vries et al., “A
randomized comparison of 1-h sodium bicarbonate hydration
versus standard peri-procedural saline hydration in patients
with chronic kidney disease undergoing intravenous contrast-
enhanced computerized tomography,” Nephrology Dialysis
Transplantation, vol. 29, no. 5, pp. 1029–1036, 2014.

[41] J. Kooiman, Y. W. J. Sijpkens, M. van Buren et al., “Rand-
omised trial of no hydration vs. sodium bicarbonate hydration
in patients with chronic kidney disease undergoing acute
computed tomography-pulmonary angiography,” Journal of
�rombosis and Haemostasis, vol. 12, no. 10, pp. 1658–1666,
2014.

14 Journal of Interventional Cardiology

[42] S. Akyuz, T. Kemaloglu Oz, S. Altay et al., “Efficacy of oral
hydration in the prevention of contrast-induced acute kidney
injury in patients undergoing coronary angiography or in-
tervention,” Nephron Clinical Practice, vol. 128, no. 1-2,
pp. 95–102, 2014.

[43] J. L. Kristeller, G. S. Zavorsky, J. E. Prior et al., “Lack of ef-
fectiveness of sodium bicarbonate in preventing kidney injury
in patients undergoing cardiac surgery: a randomized con-
trolled trial,” Pharmacotherapy: �e Journal of Human
Pharmacology and Drug �erapy, vol. 33, no. 7, pp. 710–717,
2013.

[44] F. Koc, K. Ozdemir, F. Altunkas et al., “Sodium bicarbonate
versus isotonic saline for the prevention of contrast-induced
nephropathy in patients with diabetes mellitus undergoing
coronary angiography and/or intervention: a multicenter
prospective randomized study,” Journal of Investigative
Medicine, vol. 61, no. 5, pp. 872–877, 2013.

[45] G.-Q. Gu, R. Lu, W. Cui et al., “Low-dose furosemide ad-
ministered with adequate hydration reduces contrast-induced
nephropathy in patients undergoing coronary angiography,”
Cardiology, vol. 125, no. 2, pp. 69–73, 2013.

[46] P. Boucek, T. Havrdova, O. Oliyarnyk, J. Skibova,
V. Pecenkova, and D. Sarkady, “Prevention of contrast-in-
duced nephropathy in diabetic patients with renal function
impairment: sodium bicarbonate versus sodium chloride-
based hydration,” Diabetologia, vol. 55, pp. S469–S70, 2012.

[47] G. Marenzi, C. Ferrari, I. Marana et al., “Prevention of
contrast nephropathy by furosemide with matched hydration:
the MYTHOS (induced diuresis with matched hydration
compared to standard hydration for contrast induced ne-
phropathy prevention) trial,” JACC: Cardiovascular Inter-
ventions, vol. 5, no. 1, pp. 90–97, 2012.

[48] D.-G. Kong, Y.-F. Hou, L.-L. Ma, D.-K. Yao, and L.-X. Wang,
“Comparison of oral and intravenous hydration strategies for
the prevention of contrast-induced nephropathy in patients
undergoing coronary angiography or angioplasty: a ran-
domized clinical trial,” Acta Cardiologica, vol. 67, no. 5,
pp. 565–569, 2012.

[49] T. Klima, A. Christ, I. Marana et al., “Sodium chloride vs.
sodium bicarbonate for the prevention of contrast medium-
induced nephropathy: a randomized controlled trial,” Euro-
pean Heart Journal, vol. 33, no. 16, pp. 2071–2079, 2012.

[50] V. O. Gomes, R. Lasevitch, V. C. Lima et al., “Hydration with
sodium bicarbonate does not prevent contrast nephropathy: a
multicenter clinical trial,” Arquivos Brasileiros de Cardiologia,
vol. 99, no. 6, pp. 1129–1134, 2012.

[51] M. Motohiro, H. Kamihata, S. Tsujimoto et al., “A new
protocol using sodium bicarbonate for the prevention of
contrast-induced nephropathy in patients undergoing coro-
nary angiography,” �e American Journal of Cardiology,
vol. 107, no. 11, pp. 1604–1608, 2011.

[52] M. Maioli, A. Toso, M. Leoncini, C. Micheletti, and
F. Bellandi, “Effects of hydration in contrast-induced acute
kidney injury after primary angioplasty: a randomized,
controlled trial,” Circulation: Cardiovascular Interventions,
vol. 4, no. 5, pp. 456–462, 2011.

[53] S.-W. Lee, W.-J. Kim, Y.-H. Kim et al., “Preventive strategies
of renal insufficiency in patients with diabetes undergoing
intervention or arteriography (the PREVENT Trial),” �e
American Journal of Cardiology, vol. 107, no. 10, pp. 1447–
1452, 2011.

[54] A. M. Hafiz, M. F. Jan, N. Mori et al., “Prevention of contrast-
induced acute kidney injury in patients with stable chronic
renal disease undergoing elective percutaneous coronary and

peripheral interventions: randomized comparison of two
preventive strategies,” Catheterization and Cardiovascular
Interventions, vol. 79, no. 6, pp. 929–937, 2012.

[55] C. Briguori, G. Visconti, A. Focaccio et al., “Renal insuffi-
ciency after contrast media administration trial II (REME-
DIAL II): RenalGuard system in high-risk patients for
contrast-induced acute kidney injury,” Circulation, vol. 124,
no. 11, pp. 1260–1269, 2011.

[56] W. Wróbel, W. Sinkiewicz, M. Gordon, and A. Woniak-
Winiewska, “Oral versus intravenous hydration and renal
function in diabetic patients undergoing percutaneous cor-
onary interventions,” Kardiologia Polska, vol. 68, pp. 1015–
1020, 2010.

[57] A. Vasheghani-Farahani, G. Sadigh, S. E. Kassaian et al.,
“Sodium bicarbonate in preventing contrast nephropathy in
patients at risk for volume overload: a randomized controlled
trial,” Journal of Nephrology, vol. 23, pp. 216–223, 2010.

[58] R. Cho, N. Javed, D. Traub, S. Kodali, F. Atem, and
V. Srinivasan, “Oral hydration and alkalinization is noninferior
to intravenous therapy for prevention of contrast-induced
nephropathy in patients with chronic kidney disease,” Journal
of Interventional Cardiology, vol. 23, no. 5, pp. 460–466, 2010.

[59] A. Vasheghani-Farahani, G. Sadigh, S. E. Kassaian et al.,
“Sodium bicarbonate plus isotonic saline versus saline for
prevention of contrast-induced nephropathy in patients un-
dergoing coronary angiography: a randomized controlled
trial,” American Journal of Kidney Diseases, vol. 54, no. 4,
pp. 610–618, 2009.

[60] A. Tamura, Y. Goto, K. Miyamoto et al., “Efficacy of single-
bolus administration of sodium bicarbonate to prevent
contrast-induced nephropathy in patients with mild renal
insufficiency undergoing an elective coronary procedure,”�e
American Journal of Cardiology, vol. 104, no. 7, pp. 921–925,
2009.

[61] M. Pakfetrat, M. H. Nikoo, L. Malekmakan et al., “A com-
parison of sodium bicarbonate infusion versus normal saline
infusion and its combination with oral acetazolamide for
prevention of contrast-induced nephropathy: a randomized,
double-blind trial,” International Urology and Nephrology,
vol. 41, no. 3, pp. 629–634, 2009.

[62] M. Haase, A. Haase-Fielitz, R. Bellomo et al., “Sodium bi-
carbonate to prevent increases in serum creatinine after
cardiac surgery: a pilot double-blind, randomized controlled
trial,” Critical Care Medicine, vol. 37, no. 1, pp. 39–47, 2009.

[63] P. Budhiraja, Z. Chen, and M. Popovtzer, “Sodium bicar-
bonate versus normal saline for protection against contrast
nephropathy,” Renal Failure, vol. 31, no. 2, pp. 118–123, 2009.

[64] D. Angoulvant, M. Cucherat, G. Rioufol et al., “Preventing
acute decrease in renal function induced by coronary angi-
ography (PRECORD): a prospective randomized trial,” Ar-
chives of Cardiovascular Diseases, vol. 102, no. 11, pp. 761–767,
2009.

[65] M. Maioli, A. Toso, M. Leoncini et al., “Sodium bicarbonate
versus saline for the prevention of contrast-induced ne-
phropathy in patients with renal dysfunction undergoing
coronary angiography or intervention,” Journal of the
American College of Cardiology, vol. 52, no. 8, pp. 599–604,
2008.

[66] S. L. Chen, J. Zhang, F. Yei et al., “Clinical outcomes of
contrast-induced nephropathy in patients undergoing per-
cutaneous coronary intervention: a prospective, multicenter,
randomized study to analyze the effect of hydration and
acetylcysteine,” International Journal of Cardiology, vol. 126,
no. 3, pp. 407–413, 2008.

Journal of Interventional Cardiology 15

[67] S. S. Brar, A. Y. Shen, M. B. Jorgensen et al., “Sodium bi-
carbonate vs sodium chloride for the prevention of contrast
medium-induced nephropathy in patients undergoing coro-
nary angiography: a randomized trial,” JAMA, vol. 300, no. 9,
pp. 1038–1046, 2008.

[68] E. Adolph, B. Holdt-Lehmann, T Chatterjee et al., “Renal
Insufficiency Following Radiocontrast Exposure Trial (RE-
INFORCE): a randomized comparison of sodium bicarbonate
versus sodium chloride hydration for the prevention of
contrast-induced nephropathy,” Coronary Artery Disease,
vol. 19, no. 19, pp. 413–419, 2008.

[69] P. Schmidt, D. Pang, D. Nykamp, G. Knowlton, and H. Jia,
“N-acetylcysteine and sodium bicarbonate versus N-ace-
tylcysteine and standard hydration for the prevention of
radiocontrast-induced nephropathy following coronary an-
giography,” Annals of Pharmacotherapy, vol. 41, no. 1,
pp. 46–50, 2007.

[70] E. E. Ozcan, S. Guneri, B. Akdeniz et al., “Sodium bicarbonate,
N-acetylcysteine, and saline for prevention of radiocontrast-
induced nephropathy. A comparison of 3 regimens for
protecting contrast-induced nephropathy in patients under-
going coronary procedures. A single-center prospective
controlled trial,” American Heart Journal, vol. 154, no. 3,
pp. 539–544, 2007.

[71] M. Masuda, T. Yamada, T. Mine et al., “Comparison of
usefulness of sodium bicarbonate versus sodium chloride to
prevent contrast-induced nephropathy in patients undergo-
ing an emergent coronary procedure,” �e American Journal
of Cardiology, vol. 100, no. 5, pp. 781–786, 2007.

[72] B. Dussol, S. Morange, A. Loundoun, P. Auquier, and
Y. Berland, “A randomized trial of saline hydration to prevent
contrast nephropathy in chronic renal failure patients,” Ne-
phrology Dialysis Transplantation, vol. 21, no. 8, pp. 2120–
2126, 2006.

[73] C. Mueller, P. Seidensticker, H. J Buettner et al., “Incidence of
contrast nephropathy in patients receiving comprehensive
intravenous and oral hydration,” Swiss Medical Weekly,
vol. 135, no. 135, pp. 286–290, 2005.

[74] G. J. Merten, W. P. Burgess, L. V. Gray et al., “Prevention of
contrast-induced nephropathy with sodium bicarbonate: a
randomized controlled trial,” JAMA, vol. 291, no. 19,
pp. 2328–2334, 2004.

[75] H. S. Trivedi, H. Moore, S. Nasr et al., “A randomized pro-
spective trial to assess the role of saline hydration on the
development of contrast nephrotoxicity,” Nephron Clinical
Practice, vol. 93, no. 93, pp. C29–C34, 2003.

[76] C. Mueller, G. Buerkle, H. J. Buettner et al., “Prevention of
contrast media-associated nephropathy: randomized com-
parison of 2 hydration regimens in 1620 patients undergoing
coronary angioplasty,” Archives of Internal Medicine, vol. 162,
no. 3, pp. 329–336, 2002.

[77] Task Force on Myocardial Revascularization of the European
Society of C, the European Association for Cardio–oracic S,
European Association for Percutaneous Cardiovascular I,
“Guidelines on myocardial revascularization,” European
Journal of Cardio-�oracic Surgery: Official Journal of the
European Association for Cardio-�oracic Surgery, vol. 38,
pp. S1–S52, 2010.

[78] H. S. -omsen, “European Society of Urogenital Radiology
(ESUR) guidelines on the safe use of iodinated contrast
media,” European Journal of Radiology, vol. 60, no. 3,
pp. 307–313, 2006.

[79] J. R. Brown, D. M. Pearlman, E. J. Marshall et al., “Meta-
analysis of individual patient data of sodium bicarbonate and

sodium chloride for all-cause mortality after coronary angi-
ography,”�eAmerican Journal of Cardiology, vol. 118, no. 10,
pp. 1473–1479, 2016.

[80] B. Zhang, L. Liang, W. Chen, C. Liang, and S. Zhang, “-e
efficacy of sodium bicarbonate in preventing contrast-induced
nephropathy in patients with pre-existing renal insufficiency:
a meta-analysis,” BMJ Open, vol. 5, Article ID e006989, 2015.

[81] S. Ali-Hassan-Sayegh, S. J. Mirhosseini, E. Rahimizadeh et al.,
“Current status of sodium bicarbonate in coronary angiog-
raphy: an updated comprehensive meta-analysis and sys-
tematic review,” Cardiology Research and Practice, vol. 2015,
Article ID 690308, 16 pages, 2015.

[82] J.-S. Jang, H.-Y. Jin, J.-S. Seo et al., “Sodium bicarbonate
therapy for the prevention of contrast-induced acute kidney
injury-a systematic review and meta-analysis,” Circulation
Journal, vol. 76, no. 9, pp. 2255–2265, 2012.

[83] V. Kunadian, A. Zaman, I. Spyridopoulos, and W. Qiu,
“Sodium bicarbonate for the prevention of contrast induced
nephropathy: a meta-analysis of published clinical trials,”
European Journal of Radiology, vol. 79, no. 1, pp. 48–55, 2011.

[84] S. N. Heyman, S. Rosen, M. Khamaisi, J.-M. Idée, and
C. Rosenberger, “Reactive oxygen species and the patho-
genesis of radiocontrast-induced nephropathy,” Investigative
Radiology, vol. 45, no. 4, pp. 188–195, 2010.

16 Journal of Interventional Cardiology

Copyright of Journal of Interventional Cardiology is the property of Hindawi Limited and its
content may not be copied or emailed to multiple sites or posted to a listserv without the
copyright holder’s express written permission. However, users may print, download, or email
articles for individual use.

NURS 4420 Care of Adults with Multiple Compromised Health States

Concept Paper Tips

How to begin

· Start with an outline

· Use the grading criteria to develop headers

· All students are HIGHLY encouraged to meet with the faculty grading their papers once the outline is prepared

General Writing Style

· ALL scholarly papers begin with an introduction and end with a conclusion

· Ideas should be presented in a clear, orderly, logical manner

· Ensure that tense is consistent

· Use active voice; avoid passive voice

· Avoid wordiness & redundancy – succinct is better

· Ensure clear transitions from paragraph to paragraph

· Avoid excessively long sentences

· Each paragraph should be a minimal of 3 sentences

· Ok to use first person

Referencing in text

· Reference, reference, reference!!!!!!

· Avoid secondary sources

· Use direct quotes sparingly – paraphrasing is preferred

·
Paraphrase (author(s), year)

·
Direct quote (author(s), year, page)

· Cite multiple authors when synthesizing information
(e.g. pathophysiology and referents)

Common APA mistakes

· Authors

· List authors in the same order as the article

· Do not refer to the journal or article title in the narrative – in text citations refer to the author only

· Acronyms

· Spell out word(s) the first time it is used with the acronym in parenthesis; you may then use the acronym in the remainder of the text;
example: chronic kidney disease (CKD)

**Be sure to address ALL areas of the grading criteria

Expert paper writers are just a few clicks away

Place an order in 3 easy steps. Takes less than 5 mins.

Calculate the price of your order

Type of paper needed:

Pages:

You will get a personal manager and a discount.

Academic level:

We'll send you the first draft for approval by at

Total price:

$0.00